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HUMAN IMMUNODEFICIENCY VIRUS / ACQUIRED IMMUNE DEFICIENCY SYNDROME 
 
The first patients with the acquired immunodeficiency syndrome (AIDS) were identified in 
19811, and in early 1983 a virus that caused AIDS was isolated2. At the end of 1984 it was 
proved that the new virus (called human immunodeficiency virus; HIV) belonged to the 
subfamily of lentitretroviruses and that it was a retrovirus. 
Like any virus, HIV must use the cells of another organism -its host- to survive and 
reproduce. HIV is adapted to using the cells of the human immune system, the CD4 cells.  
Retroviruses are unique in biology. Unlike other viruses, retroviruses carry their genetic code 
as RNA and they produce a unique enzyme called reverse transcriptase, which converts 
their RNA into DNA. Next the cellular machinery of the host is used for reproduction. 
 
At the end of 2004, 39.4 million people were living with HIV; the majority of these people are 
living in Sub-Saharan Africa: 25.4 million. About 14,000 new HIV infections a day occurred in 
20043. 
 
 
TREATMENT OF HIV/AIDS AND ANTIRETROVIRAL DRUGS 
 
Treatment with antiretroviral drugs has been proven to prolong survival in persons with AIDS 
and with asymptomatic HIV infection4. Furthermore, the use of highly active antiretroviral 
therapy (HAART) is associated with a decline in morbidity and mortality in HIV-infected 
persons5. HAART is an intensive therapy in which antiretroviral drugs from different groups 
are combined. 
There are four main groups of antiretroviral drugs (Table 1). Each of these groups attacks 
HIV in a different way. 
 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
The first group of antiretroviral drugs to treat HIV has become available in 1987 with the 
introduction of zidovudine6. These drugs inhibit the enzyme reverse transcriptase, which is 
produced by HIV and needed to reproduce itself in cells. These drugs are taken up by target 
cells and phosphorylated to triphosphate metabolites by cellular enzymes to produce active 
drug7. 
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Nonnucleoside Reverse Transcriptase inhibitors (NNRTIs) 
The second group of antiretroviral drugs is the NNRTIs and started to be approved in 1996. 
Nevirapine was the first NNRTI approved6. These drugs work slightly different from the 
NRTIs in that they bind in a different way to the reverse transcriptase enzyme. 
 
Protease Inhibitors (PIs) 
The third type of antiretroviral drugs are PIs, of which the first (indinavir) was approved in 
19956. PIs, as the name says, inhibit protease, an enzyme that breaks down protein and is 
one of the main enzymes that HIV uses to reproduce itself. 
 
Fusion or Entry Inhibitors 
The fourth group of antiretroviral drugs is called fusion or entry inhibitors. The first fusion 
inhibitor is enfuvirtide, which has been approved since 20038. This drug inhibits the 
attachment of HIV to the cell and in this way inhibits the reproduction of viral particles. 
 
 
Table 1 
NRTIs NNRTIs PIs Fusion Inhibitors 
Abacavir 
Didanosine 
Emtricitabine 
Lamivudine 
Tenofovir DF 
Stavudine 
Zalcitabine 
Zidovudine 
Delavirdine 
Efavirenz 
Nevirapine 
Amprenavir 
Atazanavir 
Indinavir 
fosAmprenavir 
Lopinavir 
Nelfinavir 
Ritonavir 
Saquinavir 
Tipranavir 
Enfuvirtide 
 
 
THERAPEUTIC DRUG MONITORING 
 
The role of therapeutic drug monitoring (TDM) in the management of antiretroviral agents is 
a topic of increasing interest9-14. TDM may be used when a number of important criteria are 
met14. First a more direct intermediate measure of patient response is not available; second 
a large interindividual variability in pharmacokinetic parameters should exist; furthermore, 
there should be a good relationship between plasma drug concentrations and therapeutic or 
toxic effect and a narrow range of concentrations that are effective and well tolerated. Finally 
General introduction 
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drug assays should be available. TDM for protease inhibitors, nevirapine, and efavirenz is 
useful since there is a relationship between exposure and response14, a large inter-patient 
variability exists, and the therapeutic ranges are known. Furthermore, pharmacokinetic 
parameters may be altered by the many drug interactions that have been described for 
antiretroviral drugs15, hepatic dysfunction, and non-compliance; TDM may also be useful for 
NRTIs in these cases. 
The practice of TDM is based on several disciplines, including pharmacodynamics, 
pharmacokinetics, and chemical analysis. Pharmacodynamics is the study of the 
biochemical and physiologic effects of drugs and their mechanisms of action. 
Pharmacokinetics is the study of the time course of a drug and its metabolites in the body 
after administration by any route and therefore analysis of drugs and metabolites is needed. 
Chemical analysis is the basic stone. Drugs and metabolites should be determined 
specifically and sensitively. This is particular difficult when large amounts of different drugs 
are used.  
 
 
OBJECTIVE OF THIS THESIS 
 
The objective of the studies in this thesis is to make a contribution to therapeutic drug 
monitoring of HIV treatment by bringing information from the laboratory into the clinical 
setting. 
 
The second part of the thesis is devoted to the chemical analysis. Chapter 1 describes the 
simultaneous determination of the protease inhibitors and nevirapine in human plasma. A 
bio-analytical method is a prerequisite for therapeutic drug monitoring. In chapter 2 the 
stability of protease inhibitors in plasma of HIV-infected patients was studied because long-
term stability may be needed for retrospective studies. Chapter 3 describes the cross-
reactivity of efavirenz and rifampin with a urine drug-screening assay. 
The third part of this thesis focuses on the quality of therapeutic drug monitoring services. 
The studies in chapters 4 and 5 present the results of an international quality control 
program, which was initiated to alert laboratories to deviating plasma levels of protease 
inhibitors and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine. 
Furthermore, the quality of the recommendations given by the participants of the quality 
control program, concerning adjustments of doses or regimen and possible interactions was 
described.  
In part IV of this thesis pharmacokinetic studies are described. In chapter 6 the penetration 
of lopinavir into seminal plasma is studied.  
  General introduction 
  13 
In chapter 7 and 8 the possible drug-drug interaction of tenofovir disoproxil fumarate with 
rifampin, efavirenz, and nevirapine was studied. Chapter 9 describes the results of a single-
dose nevirapine study. 
 
Finally, in the general discussion the results of this thesis are brought in a wider perspective 
and recommendations for further research are presented. 
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ABSTRACT 
 
A reversed-phase high-performance liquid chromatography method for the simultaneous 
quantitative determination of the currently available HIV protease inhibitors amprenavir, 
indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, the active nelfinavir metabolite M8, and 
the nonnucleoside reverse transcriptase inhibitor nevirapine in human plasma is described. 
The method involved liquid-liquid extraction from plasma, followed by high-performance 
liquid chromatography with an OmniSpher 5 C18 column and ultraviolet detection set at a 
wavelength of 215 nm for the protease inhibitors and 280 nm for nevirapine. The runtime was 
25 minutes. The assay has been validated over the concentration range of 0.05 to 30 mg/L 
for indinavir, nelfinavir, ritonavir and saquinavir, 0.07 to 30 mg/L for amprenavir and lopinavir, 
and 0.05 to 15 mg/L for M8 and nevirapine. 
This method proved to be simple, accurate, and precise and is useful for the therapeutic drug 
monitoring of protease inhibitors and the nonnucleoside reverse transcriptase inhibitor 
nevirapine on a routine basis. 
 Simultaneous determination of the protease inhibitors 
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INTRODUCTION 
 
The protease inhibitors and nonnucleoside reverse transcriptase inhibitors are potent 
antiretroviral drugs that have been associated with improved management of HIV infection. 
An important aim for treatment of HIV-infected patients is to bring the viral load in plasma to 
the lowest possible level, preventing disease progression. To reach this goal, therapies with 
different combinations of protease inhibitors, nonnucleoside reverse transcriptase inhibitors, 
and nucleoside reverse transcriptase inhibitors are recommended. The concentrations of the 
protease inhibitors and nonnucleoside reverse transcriptase inhibitors in plasma are a useful 
parameter for therapeutic drug monitoring, to avoid or delay viral resistance, to manage drug 
interactions, and to assess nonadherence. 
Recently two new protease inhibitors became available: amprenavir and lopinavir.  
Because of the growing number of antiretroviral drugs, many combinations of the drugs are 
administered to HIV-infected patients. Therefore, the availability of a method able to 
quantitate amprenavir, lopinavir, and nevirapine simultaneously with the other protease 
inhibitors would be useful. 
High-performance liquid chromatography (HPLC) methods for simultaneous determination of 
indinavir, ritonavir, saquinavir, and nelfinavir have been reported1-3, and the four protease 
inhibitors together with amprenavir4-10 and amprenavir and nevirapine11;12 have been 
described. However, no method is reported so far that describes the analysis of lopinavir. 
Finally, it is known that M8 is an active metabolite of nelfinavir. This article describes a 
validated method to analyze all protease inhibitors (M8 included) currently available and 
nevirapine in one analytical run based on a method previously developed in our laboratory 
for indinavir, nelfinavir, ritonavir, and saquinavir1. 
 
 
MATERIALS AND METHODS 
 
Chemicals 
Indinavir (IDV) was obtained from Merck (Rahway, NJ, USA); ritonavir (RTV), lopinavir 
(LPV), and the internal standard (IS) A860930 were obtained from Abbott (North Chicago, IL, 
USA); saquinavir mesylate (SQV) was obtained from Roche (Basel, Switzerland); nelfinavir 
(NLF) and nelfinavir hydroxymetabolite (M8) were obtained from Agouron (San Diego 
California, USA); amprenavir (APV) was obtained from Glaxo Wellcome (Stevenage, 
Hertfordshire, UK); and nevirapine was obtained from Boehringer (Mannheim, Germany). 
Super gradient acetonitrile and HPLC quality methanol were purchased from Labscan 
Analytical Sciences (Dublin, Ireland); ammonia water was purchased from OPG (Utrecht, 
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The Netherlands); and HPLC quality water and methyl tert.-butyl ether were purchased from 
Baker (Deventer, The Netherlands). All other reagents were obtained from Merck 
(Darmstadt, Germany). 
 
Standard preparation 
Stock solutions of all seven protease inhibitors and the IS were prepared in methanol and 
kept at 4°C. Stock solution of nevirapine was made in dimethylsulfoxide and kept at –20°C. 
For the preparation of the standard and quality control (QC) samples, first the stock solutions 
of amprenavir, indinavir, lopinavir, nelfinavir, M8, ritonavir, saquinavir, and nevirapine were 
diluted with blank plasma to concentrations that equaled the highest standard (30 mg/L for 
amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir and 15 mg/L for M8 and 
nevirapine). To achieve calibration concentrations of 0.05 to 30 mg/L, appropriate amounts of 
the highest standard were added to blank plasma. For the QCs, concentrations of 0.15, 1.5, 
and 7.5 mg/L for amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir and 
0.075, 0.75, and 3.75 mg/L for M8 and nevirapine were prepared from a different stock 
solution. 
 
Chromatographic equipment and conditions 
The HPLC system consisted of a model P4000 solvent delivery pump, a model AS3000 
autosampler, and a model UV1000 programmable wavelength UV detector. All these 
instruments were from Thermo Finnigan (Breda, The Netherlands). The analytical column 
was an OmniSpher 5 C18 column (150x4.6 mm ID; particle size, 5 µm) protected by a 
Chromguard RP column; both were from Varian (Middelburg, The Netherlands). Analytical 
runs were processed by Millennium32 software from Waters (Etten-Leur, The Netherlands). 
The chromatographic separation was performed at ambient temperature with gradient 
elution. The mobile phase components were acetonitrile and 50 mmol/L potassium 
phosphate adjusted to pH 5.75 with 50 mmol/L sodium phosphate. The acetonitrile 
concentration was increased linearly from 36% to 61% during a 25-minute period. In 2 
minutes, the acetonitrile concentration was returned to 36%. The column was then 
reequilibrated with the initial conditions for 3 minutes. The mobile phase flow rate was set at 
1,5 mL/min. Nevirapine was detected at 280 nm, and the protease inhibitors and IS were 
detected at 215 nm. The injection volume was 50 µL. 
 
Sample preparation 
A 500-µL aliquot of plasma (standard, QC, patient) was spiked with IS and mixed with 500 µL 
0.1 mol/L NH4OH and 5 mL methyl tert.-butyl ether. After vortexing for 1 minute and 
centrifuging for 5 minutes, the organic layer was transferred and evaporated to dryness with 
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nitrogen at 37°C. The residue was dissolved in 300 µL eluent and washed with 3 mL hexane 
and vortexed for 5 minutes. After centrifuging for 5 minutes, 50 µL of the eluent was injected 
into the chromatograph. In our laboratory, 100 samples, including QC samples and 
calibration curve, could be extracted in 1 day. The analysis takes 2 days. 
 
Specificity 
The interference from endogenous compounds was investigated by analysis of blank plasma 
from six different persons who did not use any protease inhibitor or nevirapine. No interfering 
peaks with the peaks of the protease inhibitors, nevirapine, or IS were allowed. Possible 
coadministered drugs were tested at concentrations of 50 mg/L by diluting stock solutions of 
1 mg/mL, 20 times.  
 
Accuracy, precision, recovery, lower limit of quantification and lower limit of detection 
Two replicates of three different concentrations of QC samples were analyzed in 40 separate 
runs, for determining the accuracy and precision according to National Committee for Clinical 
Laboratory Standards (NCCLS) guidelines13. The modified EP5 protocol for 1-run/day assays 
was used to calculate the intraday and interday variation.  
The accuracy was calculated as the average percentage of the nominal concentration. 
Average recovery of lopinavir, amprenavir, M8, and nevirapine was determined by comparing 
responses with those obtained by direct injection of the same amount of drug in mobile 
phase at seven different concentrations in three separate runs. For the lower limit of 
quantification, the percent deviation from the nominal concentration and the relative standard 
deviation has to be less than 20%. Samples for determining the lower limit of quantification 
were assayed as five replicates. The lower limit of detection was defined as the smallest 
quantity of drug producing a signal-to-noise ratio ≥ 3. Recovery, accuracy, and limit of 
quantification for indinavir, nelfinavir, ritonavir, and saquinavir were described before1. 
 
Stability 
The stability during sample handling of lopinavir, amprenavir, and M8 was verified, subjecting 
samples to three freeze-thaw cycles, testing the stability in plasma at room temperature and 
at –20°C, and determining the stability in blood at room temperature all at different 
concentration levels. 
Besides the stability in eluent after extraction, the stability of the standard solutions in 
methanol at 4°C was tested. Stability testing of nevirapine was limited to the stability in 
eluent. Other stability tests were performed before at our labaratory14. 
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RESULTS 
 
Chromatographic characteristics 
Figure 1A to B shows chromatograms of an extracted blank plasma and a standard plasma, 
respectively, containing the seven protease inhibitors and nevirapine. As shown, protease 
inhibitors, nevirapine, and IS are well resolved. The retention times were 1.78 minutes for 
nevirapine, 5.25 minutes for indinavir, 8.28 minutes for amprenavir, 12.49 minutes for M8, 
13.30 minutes for saquinavir, 14.34 minutes for ritonavir, 15.81 minutes for lopinavir, 17.40 
minutes for IS, and 21.54 minutes for nelfinavir. 
 
Specificity 
The six blank plasma samples showed no peaks that coeluted with the protease inhibitors, 
nevirapine or the IS. 
Of all the possible coadministered drugs tested (Table 1), delavirdine and efavirenz caused 
problems. Delavirdine coeluted with amprenavir. We decided that this was not a problem, 
because delavirdine and amprenavir are rarely coadministered in The Netherlands; 
elsewhere, it would be possible to change the gradient. Efavirenz had the same retention 
time as the IS. Therefore, there was a slight modification of the gradient. Instead of a 
gradient from 36% to 66 % acetonitrile described by Hugen, a gradient of 36% to 61 % was 
used, forcing the efavirenz to elute earlier than the IS. 
When a patient used lopinavir/ritonavir, there was a metabolite of lopinavir that coeluted with 
ritonavir. Under the conditions described, it is not possible to measure ritonavir in the 
presence of lopinavir in patient plasma. This was not considered a problem, because 
ritonavir is only added as an inhibitor of the lopinavir metabolism. 
 
Table 1: Coadministered drugs for specificity  
Acetaminophen Delavirdine Isoniazid Rifabutin 
Acyclovir Didanosine Itraconazole Rifampin 
Amphotericin B Efavirenz Ketoconazole Stavudine 
Amoxycillin Erythromycin Lamivudine Sulfamethoxazole 
Atovaquone Ethambutol Methadone Sulfametrol 
Azithromycin Famotidine Oxazepam Trimethoprim 
Clarithromycin Fluconazole Pentamidine Zalcitabine 
Clindamycin Folic acid Phenytoin Zidovudine 
Caffeine Folinic acid Pyrazinamide  
Dapsone Ganciclovir Pyrimethamine  
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Figure 1: (A) Chromatogram of a blank plasma sample containing 5 mg/L IS (B) 
Chromatogram of spiked plasma sample containing 5 mg/L IS, 3 mg/L amprenavir, 
indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, and 1.5 mg/L nevirapine and M8 
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Accuracy, precision, recovery, lower limit of quantification, and lower limit of 
detection 
The results from the validation of the method for lopinavir, amprenavir, M8, and nevirapine in 
human plasma are presented in Table 2. These results show that this method is accurate 
(average accuracy, 97-106%) and precise (interassay coefficient of variation (CV), 2.4-8.1%; 
intraassay CV, 2.3-5.9%).  
The extraction yield was found to be 95%, 91%, 92%, and 102% for lopinavir, amprenavir, 
M8, and nevirapine respectively. 
The lower limit of quantification was found to be 0.07 mg/L for lopinavir and amprenavir and 
0.05 mg/L for M8 and nevirapine. The detection limit was 0.006 mg/L, 0.013 mg/L, 0.014 
mg/L, and 0.014 mg/L for nevirapine, amprenavir, M8, and lopinavir respectively. 
The calibration curves were linear over the concentration range of 0.05 to 15 mg/L for M8 
and nevirapine and 0.07 to 30 mg/L for amprenavir and lopinavir. 
 
Table 2: Accuracy and precision of the determination of lopinavir, amprenavir, M8, and 
nevirapine in plasma 
Protease 
inhibitor 
Concentration 
(mg/L) 
Accuracy  
(% CV)  
Intraassay 
precision 
(% CV) 
(n=80) 
Interassay 
precision 
(% CV)  
(n=80) 
Recovery 
(mean (SD)) 
Lopinavir 
 
 
 
Amprenavir 
 
 
 
M8 
 
 
 
Nevirapine 
 
 
0.487 
0.974 
4.868 
 
0.500 
1.00 
5.00 
 
0.081 
1.49 
7.08 
 
0.083 
0.830 
4.15 
97 
99 
100 
 
99 
98 
98 
 
97 
100 
102 
 
101 
103 
106 
5.6 
3.3 
2.3 
 
4.9 
4.7 
4.1 
 
5.9 
3.2 
2.7 
 
3.8 
4.1 
3.7 
4.6 
3.5 
2.4 
 
8.1 
5.4 
5.1 
 
5.1 
3.7 
3.9 
 
6.2 
5.8 
4.8 
95 (3.2) 
 
 
 
91(2.3) 
 
 
 
92 (0.9) 
 
 
 
102 (5.1) 
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Stability 
The results of stability tests under various conditions are listed in Table 3. Under all 
conditions tested, lopinavir, amprenavir, and M8 proved to be stable with recoveries of at 
least 93.6 % of the initial concentration. 
 
Table 3: Stability experiments 
Protease 
inhibitor 
Concentration 
range (mg/L) 
Condition Matrix Time interval Recovery 
(mean (SD)) 
Lopinavir 
 
 
 
 
 
Amprenavir 
 
 
 
 
 
M8 
 
 
 
 
 
Nevirapine 
0.5-50 
0.15-7.3 
0.5-5.0 
0.3-3 
0.5-5.0 
3000 
0.5-5.0 
0.16-7.5 
0.5-5.0 
0.3-4.0 
0.5-5.0 
3000 
0.08-7.6 
0.07-7.0 
0.08-7.6 
0.4-4.0 
0.08-7.6 
1500 
0.08-4.5 
20°C 
-20°C 
freeze-thaw 
20°C 
20°C 
20°C 
20°C 
-20°C 
freeze-thaw 
20°C 
20°C 
20°C 
20°C 
-20°C 
freeze-thaw 
20°C 
20°C 
20°C 
20°C 
Plasma 
Plasma 
Plasma 
Blood 
Eluent 
Methanol 
Plasma 
Plasma 
Plasma 
Blood 
Eluent 
Methanol 
Plasma 
Plasma 
Plasma 
Blood 
Eluent 
Methanol 
Eluent 
8 days 
4 months 
3 cycles 
5 days 
4 weeks 
4 months 
8 days 
4 months 
3 cycles 
5 days 
4 weeks 
4 months 
8 days 
12 months 
3 cycles 
5 days 
4 weeks 
6 months 
3 weeks 
103.1 (3.6) 
99.8 (2.2) 
99.9 (3.5) 
101.8 (4.2) 
104.7 (2.5) 
103.9 (0.8) 
93.6 (4.9) 
101.7 (1.9) 
98.7 (3.6) 
104.3 (5.5) 
108.2 (1.5) 
101.0 (0.4) 
100.9 (1.9) 
96.9 (6.0) 
97.7 (0.9) 
104.4 (2.9) 
104.7 (2.5) 
 97.6 (0.3) 
 99.5 (3.7) 
 
Pharmacokinetic data 
The applicability of the assay for pharmacokinetic research in HIV-infected patients was 
demonstrated by analyzing three patient curves of amprenavir (Fig. 2A), lopinavir (Fig. 2B), 
and nevirapine (Fig. 2C). 
The pharmacokinetic data are presented in Table 4. 
According to the literature, for lopinavir the Cmin is 5.5 mg/L, the Cmax is 9.6 mg/L and the 
elimination half-life is 5 to 6 hours15. 
For amprenavir, the Cmin is 0.33 mg/L, the Cmax is 8.21 mg/L and the elimination half life is 8 
hours16. 
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For nevirapine, the Cmin is 7.2 mg/L, the Cmax is 4.0 mg/L and the elimination half life is 25 to 
30 hours17. 
 
Table 4: Pharmacokinetic data 
Patient code  A B C 
Patient characteristics 
Gender (M/F)  
Age (year) 
Weight (kg) 
Drug 
Dose (mg) 
Co-medication 
 
F 
35 
65 
Amprenavir 
1200 BID 
 
 
F 
40 
67 
Lopinavir 
400 BID 
100 mg Ritonavir BID 
 
M 
40 
80 
Nevirapine 
200 BID 
Pharmacokinetic characteristics 
Cmax (mg/L) 
Tmax (h) 
Cmin (mg/L) 
AUC0-12 (h.mg/L) 
T1/2 (h) 
 
7.75 
0.50 
0.08 
13.76 
2.83 
 
8.35 
1.00 
5.21 
52.9 
7.29 
 
5.30 
2.52 
3.30 
NDa 
NDa 
a Not determined 
 
DISCUSSION AND CONCLUSION 
 
The stability of amprenavir, lopinavir, and M8 was tested, and we found that all three were 
stable in plasma at –20°C; amprenavir and lopinavir were stable for at least 4 months, and 
M8 was stable for 12 months. After 18 months at –20°C, we found a degradation of nelfinavir 
and M8 of 30% and 12 %, respectively (not listed in Table 3). Turner et al18 also reported a 
significant degradation of both compounds stored at –20°C for a period longer than 6 months 
(83% and 73 % degradation for nelfinavir and M8, respectively, after 19 months). They 
prepared nelfinavir and M8 calibrators in drug-free heparinized plasma for the stability 
testing, which cannot be completely compared with patient samples because of the addition 
of an organic solvent in which nelfinavir and M8 are dissolved. We used patient samples for 
the stability experiments. 
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A     Patient A Amprenavir
0,0
2,0
4,0
6,0
8,0
10,0
0 1 2 3 4 5 6 7 8 9
time after ingestion (hr)
 
B      Patient B Lopinavir
0,0
2,0
4,0
6,0
8,0
10,0
0 1 2 3 4 5 6 7 8 9
time after ingestion (hr)
 
C     Patient C Nevirapine
0,0
1,0
2,0
3,0
4,0
5,0
6,0
0 2 4 6 8 10
time after ingestion (h)
 
Figure 2: Plasma concentration versus time curves for HIV-infected patients using 1200 mg 
amprenavir twice daily (A), 400 mg lopinavir twice daily (B), and 200 mg nevirapine twice 
daily (C). 
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Analytical testing of the stability of nelfinavir has been reported before6;8;11. None of the 
authors reported degradation of nelfinavir: none of them tested longer than 6 months. 
Nevertheless, we think that samples must be analyzed for nelfinavir and M8 within 6 months 
of storage at –20°C. An alternative can be storage at –70°C18. 
Some methods that measure amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in one 
run use expensive disposable cartridges for extraction5-7;10;12. 
Yamada et al4 described an assay for five protease inhibitors but did not use an IS, and the 
method was not tested for interfering drugs. Villani et al19 also did not test interfering drugs  
This method measures not only amprenavir, indinavir, nelfinavir, ritonavir, saquinavir, 
and nevirapine in one run, but also lopinavir and M8. Efavirenz was not included in this 
assay, because the recovery of efavirenz after extraction was only 20 %. 
In conclusion, a sensitive, specific, and validated assay for the simultaneous determination 
for the currently available protease inhibitors, M8, and nevirapine is described. This method 
can be used in a hospital laboratory for therapeutic drug monitoring of the protease inhibitors 
and nevirapine in patient plasma and for pharmacokinetic studies in HIV-infected patients. 
The calibration curves for lopinavir (0.07-30 mg/L), amprenavir (0.07-30 mg/L), and 
nevirapine (0.05-15 mg/L) are appropriate for clinical drug monitoring16;17. 
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ABSTRACT 
 
Background: Stability of the protease inhibitors amprenavir, indinavir, lopinavir, nelfinavir, 
M8, ritonavir, and saquinavir in plasma at low temperatures is only studied in calibration 
samples. We investigated the effects of storage at -20°C and -80°C on the stability of 
protease inhibitors in plasma of HIV-infected patients. 
Methods: Stability was determined by analyzing plasma samples stored 0 to 18 months. 
Plasma concentrations were compared with those at start of the study. 
Results: Concentrations found after 18 months of storage in the freezer varied between 95% 
and 108% of the initial concentration. 
Conclusions: Plasma samples of HIV-infected patients stored at -20°C or -80°C can still be 
analyzed after 18 months. 
Stability of the protease inhibitors 
  37 
INTRODUCTION 
 
The protease inhibitors are potent antiretroviral drugs that have been associated with an 
improvement in the treatment of human immunodeficiency virus (HIV) infection. The 
concentrations of the protease inhibitors (PIs) in plasma are useful parameters for 
therapeutic drug monitoring (TDM), in order to avoid or delay viral resistance, to assess 
toxicity, to manage drug-drug-interactions, and to assess non-adherence1. 
Numerous high-performance liquid chromatography (HPLC) methods have been published 
for each individual PI and for the simultaneous determination of several PIs2. These assays 
can be used for patient care and for retrospective and prospective pharmacokinetic studies. 
Although many assays have been published, and analytical stability testing during assay 
validation is typical, long-term stability of the PIs in patient plasma has not been studied yet. 
There are indications that nelfinavir and its active hydroxy–t-butyl-amide (M8) show 
degradation when stored at -20°C3. Furthermore, Egge-Jacobsen4 reported degradation of 
amprenavir at -20°C, but both these studies were performed in spiked blank plasma. 
For retrospective clinical studies in particular it is of great importance to know the stability of 
the PIs in patient plasma in the freezer. 
The aim of this study was to describe the stability of the PIs amprenavir, indinavir, lopinavir, 
nelfinavir, M8, ritonavir, and saquinavir in HIV-infected patient samples at –20°C and –80°C 
during 18 months. 
 
 
MATERIAL AND METHODS 
 
This study used HIV-infected patient samples that were collected from therapeutic drug 
monitoring samples during the first week of august 2003. All samples were collected in 
heparinized hard plastic tubes. The blood samples were centrifuged at 2,500 x g for 10 
minutes. Plasma of patients using the same protease inhibitor were pooled and assayed in 
triplicate immediately, being the baseline value. Aliquots of the samples were stored at -20°C 
and -80°C. After 3, 6, 12, and 18 months samples were analyzed in triplicate to assess the 
concentrations and to determine the possible degradation. 
Concentrations of amprenavir, indinavir, lopinavir, nelfinavir, M8, ritonavir, and saquinavir 
were determined by a previously described validated HPLC method with ultraviolet (UV) 
detection5. The accuracies of the method ranged from 97 % to 106% depending on the 
concentration level. Intraday precisions were 2.3% to 5.6% and interday precisions were 
2.4% to 8.1%. The lower limit of quantification was found to be 0.04 mg/L for indinavir, M8, 
nelfinavir, ritonavir, and saquinavir and 0.07 mg/L for amprenavir and lopinavir. 
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The accuracy of the assay was externally tested by the International Program for Quality 
Control of Therapeutic Drug Monitoring in HIV Therapy6;7. During the time of this study, we 
participated 3 times in the quality control program, in October 2003, and March and October 
2004. In this program 20% limits around the nominal concentrations are considered to be 
appropriate thresholds for a satisfactory measurement. Results obtained from all 
measurements of all three rounds of the International Quality Control Program were within 
these limits except for one. For amprenavir all 9 results deviated less than 17% from the 
nominal concentration. For indinavir all 9 results deviated less than 12% from the nominal 
concentration. For lopinavir and nelfinavir all 9 results deviated less than 14% from the 
nominal concentration. For M8 8 results deviated less than 11% and one result deviated 22% 
from the nominal concentration. For ritonavir and saquinavir all 9 results deviated less than 
15% and 18% respectively from the nominal concentration. Results of the ongoing analysis 
for assessment of long-term stability should remain within 15% of their originally determined 
concentration according to the guidelines of the FDA for bioanalytical method validation8. 
 
 
Table 1: Mean concentrations after storage at -20°C or -80°C (%CV) 
T Time 
(m) 
IDV APV LPV NLF M8 RTV SQV 
-20°C 0 
3 
6 
12 
18 
2.17 (6.6) 
2.07 (0.9) 
1.93 (2.3) 
2.12 (1.8) 
2.28 (2.0) 
3.17 (4.9) 
2.92 (2.4) 
2.44 (0.9) 
3.08 (4.3) 
3.01 (0.3) 
9.61 (0.9) 
9.32 (2.7) 
9.67 (0.3) 
9.95 (2.1) 
10.34 (3.6) 
2.29 (1.0) 
2.34 (1.9) 
2.12 (0.3) 
2.33 (3.4) 
2.31 (3.0) 
0.75 (1.2) 
0.72 (1.1) 
0.62 (0.9) 
0.69 (3.0) 
0.74 (4.1) 
1.32 (5.5) 
1.30 (0.7) 
1.25 (2.7) 
1.34 (1.7) 
1.41 (2.8) 
0.31 (0.6) 
0.30 (1.0) 
0.29 (1.4) 
0.30 (2.1) 
0.33 (8.0) 
-80°C 0 
3 
6 
12 
18 
2.17 (6.6) 
2.05 (1.5) 
2.03 (0.7) 
2.20 (4.5) 
2.31 (2.4) 
3.17 (4.9) 
3.07 (4.2) 
2.82 (1.0) 
3.21 (1.0) 
3.25 (2.7) 
9.61 (0.9) 
9.57 (1.1) 
9.73 (1.2) 
10.12 (2.3) 
10.26 (3.3) 
2.29 (1.0) 
2.33 (0.7) 
2.21 (0.4) 
2.47 (2.2) 
2.45 (3.2) 
0.75 (1.2) 
0.73 (0.7) 
0.67 (2.2) 
0.71 (2.1) 
0.77 (2.1) 
1.32 (5.5) 
1.28 (0.5) 
1.28 (0.9) 
1.36 (3.1) 
1.39 (2.8) 
0.31 (0.6) 
0.30 (1.4) 
0.29 (2.1) 
0.30 (2.9) 
0.32 (4.5) 
T= storage temperature, IDV= indinavir, APV= amprenavir, LPV= lopinavir, NLF= nelfinavir, 
RTV= ritonavir, SQV= saquinavir) 
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RESULTS 
 
The baseline concentrations of the samples were 3.17, 2.17, 9.61, 2.29, 0.75, 1.32, and 0.31 
mg/L for amprenavir, indinavir, lopinavir, nelfinavir, M8, ritonavir, and saquinavir respectively. 
The results are presented in Table 1. The relative concentrations (%) of amprenavir, 
indinavir, lopinavir, nelfinavir, M8, ritonavir, and saquinavir from samples stored at -20°C and 
-80°C were calculated at 3, 6, 12, and 18 months after storage with the baseline value set at 
100%. The relative concentrations (%) were plotted versus the storage time for each 
investigated drug and at each investigated temperature (Fig. 1). The relative concentrations 
determined at two temperatures after 18 months were not different from the baseline values, 
being 106%/105%, 103%/95%, 107%/108%, 107%/101%, 102%/98%, 105%/107%, and 
105%/108% for indinavir, amprenavir, lopinavir, nelfinavir, M8, ritonavir, and saquinavir 
respectively at -80°C/-20°C, indicating that the PIs are stable in plasma of HIV-infected 
patients when stored at -20°C or at -80°C for 18 months. 
Almost all relative concentrations were found to be between the thresholds of 85% to 115 %, 
only the mean relative concentrations for amprenavir and M8 after 6 months of storage at -
20°C were just below the 85% threshold, being 77% and 83% respectively. 
 
 
DISCUSSION 
 
This study revealed that after 18 months of storage at either -20°C or -80°C, there is no 
degradation of any of the PIs amprenavir, indinavir, lopinavir, nelfinavir, M8, ritonavir, or 
saquinavir in plasma of HIV-infected patients.  
The concentrations of the PIs tested in this study were 3.17, 2.17, 9.61, 2.29, 0.75, 1.32, and 
0.31 mg/L for amprenavir, indinavir, lopinavir, nelfinavir, M8, ritonavir, and saquinavir 
respectively, which are therapeutic concentrations for the PIs in question9. 
Although the protease inhibitors used have been available since the late nineties, the stability 
of these drugs in plasma of HIV-infected patients has not been studied well. In Table 2A and 
2B all stability experiments during validation of HPLC assays are listed. In Table 2A the 
studies are listed that reported no degradation of any of the PIs. The storage time of these 
studies ranged from 14 days to 6 months and the samples were stored at -20°C and -70°C. 
In Table 2B experiments are listed that reported degradation of protease inhibitors. Only 
degradation of nelfinavir, M83;5, and amprenavir4 was reported. All experiments listed in 
Table 2A and almost all experiments presented in Table 2B used spiked samples (calibration 
samples) for stability testing. These samples were prepared by adding PIs, which were 
dissolved in organic solvents, to drug-free plasma. 
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Figure 1: Relative concentrations of the protease inhibitors in patient plasma during storage 
at -20°C at -80°C, mean and standard deviations, the dashed vertical lines represent the 
thresholds (85% and 115%) 
 
These calibration samples are not completely comparable to patient samples, because of the 
different composition. The calibration samples contain organic solvents and do not contain 
possible metabolites of the PIs or any comedication. In Table 2B patient samples containing 
nelfinavir and M8 showed degradation at -20°C5. This is not confirmed by our present study. 
The study of 2003 existed of analyzing 5 different patient samples, once at the time of blood  
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Table 2 A: Acceptable stability 
Pis M T Time Rfs 
NLF 
IDV, NLF, SQV, RTV 
APV, IDV, LPV, M8, NLF, RTV, SQV 
APV, IDV, NLF 
IDV, RTV, SQV 
IDV, NLF, RTV, SQV 
APV, IDV, NLF, RTV, SQV 
APV, NLF, RTV, SQV 
LPV 
IDV, NLF, RTV, SQV 
APV, NLF, RTV, SQV, LPV 
IDV, RTV, NLF, SQV, APV 
IDV, RTV, SQV, NLF, LPV 
M8 
APV, LPV 
IDV, NLF, RTV, SQV 
IDV, APV, SQV, RTV, LPV, NLF 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
-20°C 
-20°C 
-20°C 
-20°C 
-20°C 
-20°C 
-20°C 
-20°C 
-20°C 
-20°C, -65°C 
-20°C 
-70°C 
-20°C 
-20°C 
-20°C 
-20°C 
-20°C 
4.5 months 
3 months 
6 months 
1 month 
14 days 
6 months 
6 months 
6 months 
1 month 
1.5 month 
1 month 
6 months 
3 months 
12 months 
4 months 
2 months 
1 month 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
4 
5 
5 
25 
26 
PIs=protease inhibitors, APV=amprenavir, IDV=indinavir, LPV=lopinavir, NLF=nelfinavir, 
RTV=ritonavir, SQV=saquinavir, M=material. SP=spiked plasma, T=storage temperature, 
Time =storage time, Rfs=references 
 
 
Table 2B: Degradation of protease inhibitors 
PIs M Temperature Time % Degradation Refs 
APV 
NLF 
NLF 
M8 
M8 
NLF 
M8 
SP 
SP 
PS 
SP 
PS 
SP 
SP 
-20°C 
-20°C  
-20°C 
-200C 
-20°C 
-70°C 
-70°C 
3 months 
18 months 
18 months 
18 months 
18 months 
12 months 
12 months 
21-24 
83 
30 
73 
11 
3 
10 
4 
3 
5 
3 
5 
3 
3 
PIs=protease inhibitors, M=material, SP=spiked plasma, PS=patient sample, 
APV=amprenavir, NLF=nelfinavir 
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sampling, and once after storage at -20°C for 18 months; the mean degradation was 
reported. In our present study the baseline concentrations and the concentrations after 3, 6, 
12, and 18 months were analyzed in triplicate in contrast with the samples of 20035. 
Obviously, the concentrations reported in this study are more reliable, because the samples 
were analyzed in triplicate at several time points during storage. 
The results of this study show a slightly lower recovery at 6 months, which can be explained 
by different causes. 
Any analytical assay is subject to some variation. According to the guidelines for method 
validation for bio-analysis of drugs8, quality control samples are allowed to deviate 15% from 
the true value. Also the US Clinical Laboratory Improvement Amendments (CLIA) of 1988 
allow a maximum of 20% deviation10.  
Furthermore, it is known that PIs have poor solubility in aqueous solutions11 and their 
solubility is pH dependent. In general, these drugs are poorly soluble at physiological pH 
(7.4)12. Especially at low temperatures crystal formation is possible and therefore, it is of 
great importance to mix the samples thoroughly after defrosting. This phenomenon might be 
the reason for the degradation of nelfinavir and amprenavir in table 2B and also for the 
slightly lower recovery found at month 6 in this study.  
 
In conclusion, the results of this study showed that the PIs amprenavir, indinavir, lopinavir, 
nelfinavir, M8, ritonavir, and saquinavir are stable for at least 18 months at -20°C or -80°C in 
plasma of HIV-infected patients. 
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ABSTRACT 
 
The InstaCheck multidrug Screen Panel (Forefront Diagnostics, San Diego, CA) tested false-
positive for tetrahydrocanabinol and morphine for healthy volunteers using efavirenz and 
rifampin respectively. 
Researchers, technicians, and clinicians should be aware of the possibility of false-positive 
results when using the InstaCheck multidrug Screen Panel and we recommend that each 
laboratory evaluate rifampin and efavirenz interference with the drug screening assay in use. 
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Screening for drugs of abuse in urine with immunoassays is common in phase I healthy 
volunteer pharmacokinetic studies. This screening method is easy to perform, sensitive, and 
gives a quick result concerning unauthorized drug use by the healthy volunteers at entrance 
or during the study. However, false-positive results for 1 of the tested drugs of abuse may 
occur, as described in the package insert of the test panel. We observed false-positive 
results in urine samples from 2 different phase I studies after testing with the InstaCheck® 
multidrug Screen Panel. The InstaCheck® is a one-step immunoassay in which chemically 
labeled drugs compete for limited antibody binding sites with drugs that may be present in 
urine1. 
In 2 different healthy volunteer pharmacokinetic studies published elsewhere, the ENRICO 
study2 and the TENORI study3, we used the InstaCheck® multidrug Screen Panel (Forefront 
Diagnostics, San Diego, CA) to monitor the use of tetrahydrocannabinol, morphine, cocaine, 
and amphetamines. The urine drug screens were performed as outlined in the package 
insert1. No additional confirmative bioanalytical methods were executed. 
In the ENRICO study, negative drug screen results were obtained for all 24 subjects on day 1 
of the study and at day 10, after multiple doses of the antiretroviral protease inhibitors, 
nelfinavir/ritonavir 1875/200 mg once daily. On day 20 of the study, after multiple doses of 
nelfinavir/ritonavir + the antiretroviral nonnucleoside reverse transcriptase inhibitor efavirenz 
600 mg once daily, all 24 subjects (100%) tested positive for tetrahydrocannabinol, at 14 
hours after the last medication intake. Tests were repeated to ensure proper materials and 
operating procedures. All subjects were counseled by the study physician to exclude the use 
of tetrahydrocannabinol. None of the 24 volunteers reported the use of tetrahydrocannabinol. 
In the TENORI study, no positive test results were seen at start and in the first part of the 
study after 9 consecutive doses of the antiretroviral drug tenofovir disoproxil fumarate (DF) 
300 mg once daily. At the end of the second part of the study, after multiple doses of 
tenofovir DF and the tuberculostatic drug rifampin 600 mg once daily, 4 of 24 subjects (17%) 
tested positive for morphine use, at approximately 13 hours after the last medication intake. 
The screening was repeated a couple of hours after medication intake for 1 subject who 
tested positive and for 1 subject who tested negative. Both tests were positive for morphine. 
The healthy volunteers who tested positive for morphine were then counseled by the study 
physician to exclude the use of morphine. None of the volunteers reported the use of 
morphine. Furthermore, all urines that tested positive with the InstaCheck® multidrug Screen 
Panel were repeated using Triage (Biosite Diagnostics, San Diego, CA) and tested negative. 
Neither efavirenz nor rifampin cross-reactivity are mentioned in the package insert of 
the InstaCheck®. Both drugs and their metabolites are at least partly excreted by urine. 
Cross-reactivity of efavirenz with marijuana tests has been reported before4. The results 
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seen in the ENRICO study were so profound that other explanations to the observation than 
cross-reactivity between efavirenz and tetrahydrocannabinol are unlikely.  
There are reports on the interference of rifampin with opiate immunoassays5;6. Our finding of 
17% cross-reactivity is in line with earlier reported 12% cross-reactivity7.  
As a result of the close monitoring of the volunteers and the existing reports of similar cross-
reactivity we are convinced that other explanations for the false-positive results are unlikely. 
 
Researchers, technicians, and clinicians should be aware of the possibility of false-positive 
results for tetrahydrocannabinol after efavirenz use and for morphine after rifampin use, 
when testing with the InstaCheck® multidrug Screen Panel. Furthermore, we recommend that 
each laboratory evaluate rifampin and efavirenz interference with the drug screening assay in 
use. 
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ABSTRACT 
 
Introduction: Since 1999 an international interlaboratory quality control program for analysis 
of antiretroviral drugs in plasma is ongoing. Results of the third round of this program are 
presented. 
Methods: Quality control samples were prepared by spiking drug-free plasma with varying 
concentrations of the currently available protease inhibitors and the nonnucleoside reverse 
transcriptase inhibitors efavirenz and nevirapine. Thirty-three laboratories participated in the 
program and were requested to analyze the quality control samples. 
Results: Results were from 30 laboratories. Of all measurements, 82% were performed 
within 80%-120% accuracy limits. Only 3 laboratories performed all their measurements 
within these limits, and 12 participants reported at least 90% of their analyses within the 
acceptance range. Mean accuracy for low drug concentrations was worse than for medium 
and high concentrations. The percentage of satisfactory measurements for the 6 laboratories 
that participated for the third time in the program increased from 54% in the first round to 
85% in the third round. 
Conclusions: The program revealed a large variability in the laboratories’ ability to measure 
antiretroviral drugs accurately. This variability may have important implications for 
therapeutic drug monitoring of these drugs and pharmacokinetic studies. Interlaboratory 
testing is useful to alert laboratories to previously undetected analytical problems. 
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INTRODUCTION 
 
There has been increasing interest in bio-analysis of protease inhibitors (PIs) and 
nonnucleoside reverse transcriptase inhibitors (NNRTIs) in recent years. Many high-
performance liquid chromatographic (HPLC) assays have been published for quantitation of 
these drugs in plasma1. These analytical methods are used to study the pharmacokinetics 
and drug interactions of these drugs, and drug level measurements of PIs and NNRTIs are 
applied to individualize drug dosing (Therapeutic Drug Monitoring, TDM)2. 
In view of the wide application of bioanalytical methods for antiretroviral drugs and the clinical 
relevance of these applications, our department has initiated the International Interlaboratory 
Quality Control Program for Therapeutic Drug Monitoring in HIV infection. The aim of this 
program is to alert laboratories to deviating results with respect to the analysis of PIs and 
NNRTIs, and thereby enable them to improve their performance. 
The first round of the program was performed in 1999 and was limited to nine laboratories 
and to the measurement of four PIs (indinavir, nelfinavir, ritonavir, and saquinavir)3. The 
present report describes the results of the mature program, as reflected in the third round 
that took place in 2001. This third round of the program included 33 participating laboratories. 
In addition, the program was extended to the measurement of the PIs amprenavir and 
lopinavir and the NNRTIs efavirenz and nevirapine. 
 
 
MATERIALS AND METHODS 
 
Materials 
Indinavir was obtained from Merck & Co., Inc (Rahway, NJ, USA), ritonavir and lopinavir from 
Abbott Laboratories (North Chicago, IL, USA), saquinavir mesylate from Hoffmann-La Roche 
(Basel, Switzerland), nelfinavir mesylate from Agouron Pharmaceuticals Inc. (San Diego, 
California, USA), amprenavir from GlaxoWellcome (Stevenage, Hertfordshire, UK), 
nevirapine from Boehringer (Mannheim, Germany) and efavirenz was provided by Du Pont 
Pharmaceuticals (Wilmington, USA). All drugs had a high purity (>97%). PIs were kept at 
room temperature and NNRTIs were stored at 4°C. Methanol and dimethyl sulfoxide were 
purchased from Merck (Darmstadt, Germany). Drug-free plasma was obtained from the 
regional blood bank and was stored at –20°C. 
 
Preparation and dispatch of the quality control plasma samples 
PIs were dissolved in methanol, nevirapine and efavirenz in dimethyl sulfoxide. These 
solvents were used because the antiretroviral drugs were soluble and stable in these fluids. 
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Three quality control (QC) samples were prepared by spiking plasma with three different 
concentrations of the PIs amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir. 
Three other QC samples contained the NNRTIs efavirenz and nevirapine. All concentrations 
(Table1) related to the active part of the chemical compound, not to the salt or esterificated 
form. 
QC samples were dispensed in polypropylene tubes and were stored at –20°C. Stability 
under these and other conditions was assessed and reported previously4-6. QC samples 
were analyzed in duplicate with our own validated HPLC methods4;6;7 as a confirmative check 
before samples were released for the QC program. Measurements were not allowed to 
deviate more than 5% from the true values. 
The samples were packed on dry ice and dispatched to 33 laboratories in the United States, 
Europe, Canada, and Australia. Transit time of samples was 4 days at most. The laboratories 
were requested to analyze the QC samples within 6 weeks and return their results with 
details about their assays. 
 
Data analysis 
Descriptive statistics were calculated after standardization of all laboratory results to 
percentages with reference to the true value. By subtracting 100% from these percentages, 
the percentage bias from the true concentration (inaccuracy) was calculated. Twenty percent 
limits around the true values were considered to be appropriate threshold values for 
satisfactory measurements. 
Analysis of variance (ANOVA) was used to evaluate the simultaneous effect of two factors, 
the drug to be measured and the concentration level (low, medium and high), on the absolute 
inaccuracy. Measurements of different drugs within the same laboratory were regarded as 
related to each other, and measurements of the different concentration levels of the same 
drug were also considered to be associated. Therefore, both drug to be measured and 
concentration level were repeated-measures (within subjects) factors in the analysis of 
variance. All statistical evaluations were performed using SPSS for Windows, (version 10.0: 
SPSS Inc. Chicago, Ill, USA). A p-value of < 0.05 was considered statistically significant in all 
analyses. 
 
Reporting of results and sources of error 
All participants were informed about their own performance and about the performance of all 
participants, as median inaccuracy and the range of inaccuracies were presented 
anonymously for all separate measurements. Results of all participants were also presented 
graphically.  
Together with the results, an error evaluation form was sent to laboratories that reported 
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unsatisfactory results in one of their measurements. They were asked to complete one form 
for every drug with deviating results. This form categorized errors as follows (derived from 
similar inquiries8,9): methodological problems (M), technical problems (T), clerical problems 
(T), survey problems (S), and other (O). 
 
 
RESULTS 
 
Laboratories and analytical methods 
Results were received from 30 out of 33 laboratories. Two laboratories did not report a 
reason for not returning results; one laboratory no longer measured antiretroviral drugs. Of 
the 30 responding laboratories, 28 were hospital laboratories and two were commercial 
laboratories. Of the 30 participants, 30% were from the United States, 60% from Europe, and 
the remaining 10% from Canada and Australia. All participants that provided details about 
their assays reported using HPLC. 
Three laboratories were not able to measure the low concentrations of amprenavir, indinavir, 
or ritonavir, as their lower limits of quantitation were too high. Another participant reported an 
inability to measure the high concentration of saquinavir because this concentration was not 
within the range of the method. 
 
Accuracy of measurement 
A maximum number of 24 measurements (3 for each drug) were performed by the 
laboratories. Table 1 presents the results arranged by drug and concentration level. The 
performance of individual laboratories is displayed in Figure 1. 
Only three laboratories reported all their results within the acceptance range (80%-120% 
accuracy). One laboratory (nr 30, Fig. 1) did not report any satisfactory result. Twelve out of 
30 participants reported at least 90% of their results within the acceptance range. Twelve 
laboratories used analytical methods that appeared to have a large systematic error in one 
direction, as all measured concentrations of at least one drug were either above or below the 
80%-120% accuracy limits. 
 
Effect of drug to be measured and concentration level on accuracy 
Descriptive analysis did not suggest large differences in mean absolute inaccuracies for 
measurements of the eight antiretroviral drugs (Table 1). This was confirmed by an ANOVA, 
which was performed for those laboratories that were able to measure all eight drugs (n=13). 
There was no significant main effect of the drug to be measured on the absolute inaccuracy 
(F(2.783, 33.392)=0.955, p=0.42). However, the concentration level to be analyzed had a  
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Table 1: Results, subdivided by drug and concentration level 
Drug N Concentration 
level                         (mg/L) 
% Inaccuracy 
Median 
(min-max) 
N and % within 80-
120% acceptance 
range 
Amprenavir 21 Low  
Intermediate  
High  
 0.24 
 2.2 
 7.2 
13 (0-100) 
8 (1-65) 
8 (2-49) 
17/21 
18/21 
17/21 
 
83% 
Indinavir 27 Low  
Intermediate 
High  
 0.13 
 2.3 
11.7 
15 (1-2218) 
12 (1-334) 
11 (0-98) 
16/27 
20/27 
21/27 
 
70% 
Lopinavir 23 Low  
Intermediate  
High  
 1.2 
 4.7 
11.7 
7 (1-70) 
5 (1-46) 
6 (0-44) 
17/23 
19/23 
19/23 
 
80% 
Nelfinavir 28 Low  
Intermediate  
High  
 0.32 
 2.1 
 6.4 
9 (2-92) 
8 (0-207) 
8 (1-61) 
24/28 
23/28 
24/28 
 
85% 
Ritonavir 26 Low  
Intermediate  
High  
 0.24 
 2.4 
 9.7 
7 (0-41) 
9 (1-28) 
16 (1-148) 
16/26 
23/26 
24/26 
 
81% 
Saquinavir 27 Low  
Intermediate  
High  
 0.11 
 1.4 
 5.1 
9 (0-446) 
6 (0-35) 
5 (0-28) 
19/27 
25/27 
25/27 
 
85% 
Efavirenz 23 Low  
Intermediate  
High  
 0.46 
 3.7 
 6.6 
12 (1-80) 
9 (0-71) 
8 (0-78) 
18/23 
19/23 
19/23 
 
81% 
Nevirapine 18 Low  
Intermediate  
High  
 0.50 
 3.2 
 6.9 
8 (2-71) 
9 (1-19) 
9 (0-24) 
16/18 
18/18 
17/18 
 
94% 
Abbreviations: 
N:  number of measurements 
Min: minimum value 
Max: maximum value 
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Figure 1: Performance of individual laboratories. Diagram shows the results for all 
measurements arranged by laboratory. Results for individual measurements are depicted by 
points; the lines represent the thresholds (80%-120%) 
 
 
significant effect on the absolute inaccuracy ((F (1.035,12.421)=7.447, p=0.02). The mean  
absolute inaccuracy over all drugs for all 13 laboratories was 20.0% for low concentrations, 
11.4% for medium concentrations, and 11.1% for high concentrations. Pairwise comparisons 
were performed at a Bonferroni-adjusted significance level for each separate test, keeping 
the overall type I-error rate at 0.05. These comparisons showed a significant difference 
between the absolute inaccuracies for measurements of the low drug levels versus the 
medium drug levels (p=0.041), and a trend towards a significant difference (p=0.06) between 
low level versus high level measurements. 
However, no significant differences between measurements of the medium and high drug 
levels were observed (p=1.0). The interaction between drug to be analyzed and drug level 
was not significant (F (1.941, 23.294)=1.419, p=0.26). 
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Table 2: Explanations for accuracies outside 80-120% fixed limits 
 Number % of total 
METHODOLOGIC PROBLEMS   
M1 Instrument problem -  
M2 Method change before QC-program 
M3 Method not validated for all PIs 
M Subtotal 
 
18 
18 
 
 
23.4 
TECHNICAL PROBLEMS   
T1 Dilution error 5  
T2 Incorrect pipetting (other than dilution) 4  
T3 Misidentification of the peak 1  
T4 Calculations performed incorrectly 3  
T5 Run accepted in non-linear range   
T6 Run accepted even though controls were out of range 
T7 Aging stock solutions 
T8 Stock solutions not made of pure substances 
T9 Below quantitation limit 
T Subtotal 
9 
17 
3 
2 
44 
 
 
 
 
57.1 
CLERICAL ERRORS   
C1 Results reported in wrong unit   
C2 Decimal point error 1  
C3 Transcriptive error into questionnaire 3  
C Subtotal 4 5.2 
SURVEY   
S1 Specimen problem   
S2 Criteria for acceptance too narrow   
S Subtotal 0 0 
OTHER   
O1 Unexplained/unassigned cause 11  
O Subtotal 11 14.3 
   
Total 77 100 
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Sources of error 
Twenty-seven participating laboratories reported at least one measurement with an 
inaccuracy of more than 20%. Nineteen laboratories returned their error forms. 
Reported errors are presented in Table 2. Every single inaccuracy for which an explanation 
was reported was included in the table. There was a wide variability in explanations for 
deviating results. Frequent sources of error were the use of an analytical method that was 
not (or not properly) validated and the use of aging stock solutions. 
Five out of six laboratories, that participated for the third time in this Quality Control Program, 
improved their performance in time. The overall percentage of acceptable measurements for 
these six laboratories increased from 54 % in the first round to 83% in the second round and 
85% in the third round. 
 
 
DISCUSSION 
 
The results of this program show large variability in the ability of laboratories to measure 
antiretroviral drugs accurately. Measurement of these drugs needs to be improved in a 
number of laboratories that participated in the program. 
The quality control program was designed to represent the reality encountered in the 
laboratories as close as possible. Therefore, it was decided not to use lyophilized plasma 
that should be reconstituted. Furthermore, no reference substances or reference plasma 
samples were distributed. The major difference between the QC samples and routine 
samples related to the presence of other drugs or metabolites, which were absent in the QC 
samples. 
As a result of the similarities between QC samples and real samples, it can be inferred that 
the results of this quality program provide a measure of the rigor (or effectiveness) of the 
regular intralaboratory (internal) quality assurance in the participating laboratories. 
On the other hand, it cannot be excluded that laboratories made extra efforts to achieve 
accurate results in this program10. This means that the results of the quality control program 
could also represent the best performance of the participants. 
In this program, results obtained by a certain laboratory were considered acceptable if they 
fell within preset 80%-120% limits for accuracy. The 20% threshold was based on guidelines 
for method validation for bio-analysis of drugs11, as 20% deviations are often used as a fixed 
criterion for inaccuracy at the lowest level of quantitation. The 20% limits are also 
comparable to maximal allowable error specifications for drug measurements according to 
the U.S. Clinical Laboratory Improvement Amendments (CLIA) of 198812. 
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The large interlaboratory variability in performance with respect to antiretroviral drug 
measurements may have important implications for TDM. Based on the inaccurate 
measurements, wrong dose adjustments might occur or patients might be advised not to 
adjust doses when an adjustment might be necessary. This may lead to resistance 
development, therapy failure, and concentration-related adverse events. In this respect, it is 
of special concern that low concentrations were more difficult to measure than medium or 
high concentrations. This is because the lowest antiretroviral drug concentrations in a dosing 
interval (trough concentrations) are particularly useful to measure; adequate trough levels 
appear to be most critical predictor for the efficacy of PIs2. 
Fortunately, the quality control program alerted the laboratories to inaccuracies and invited 
them to inquire possible sources of error. Our findings with respect to the possible 
explanations for inaccuracies (distribution over the error categories) differed from other 
studies8,9,13. In our program, the category of “technical problems” accounted for 57% of the 
errors (Table 2) while the studies of Hoeltge et al9, Steindel et al8, and Jenny et al13 found 
19%, 19% and 17% for this category respectively. This difference can be probably ascribed 
to the use of complex assays with difficult sample preparation that are required for analysis 
of antiretroviral drugs (compared to automatic assays for many other drugs). In the category 
of “methodological problems” all problems were caused by inappropriate validation of the 
assays. The participants concerned did not check their assays for interference of other PIs 
than the assay was developed for, while the QC samples contained all the PIs. 
It seems that corrective action could prevent many errors in the future, although some 
failures were unexplained, (15% in our study). In fact, it appeared that the laboratories that 
were participating in the quality control program for the third time had better results in the 
third round than in the first round. It is expected that at least some of these improvements 
over time also affect the performance on real samples. 
In conclusion, the program revealed a large variability in the performance of laboratories to 
measure antiretroviral drugs. The program alerted a number of laboratories to previously 
undetected analytical problems. This will enable them to improve their assays. In the future 
more agents will be included in the quality control program (e.g. nucleoside reverse 
transcriptase inhibitors). All laboratories measuring these antiretroviral drugs are invited to 
participate in this program.  
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ABSTRACT 
 
The third round of the International Interlaboratory Quality Control Program for Therapeutic 
Drug Monitoring in HIV-infection (QC-program) consisted of the analysis not only of plasma 
samples but also of patient cases. The case was composed of different topics related to the 
therapeutic drug monitoring of antiretroviral drugs. The participants were asked to give 
recommendations concerning dose adjustments, changes to the regimen, and drug-drug 
interactions, to observe whether the expert recommendations were comparable. Of the 30 
participants of the QC-program, 16 returned their comments and recommendations with 
regard to the patient case. The drug level was easy to judge, as ± 90% were able to correctly 
do so. Almost half of the recommendations (46%) given were satisfactory. Levels of 
knowledge regarding HIV treatment appeared to be variable among the respondents and for 
this reason were partly incomparable. 
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INTRODUCTION 
 
The use of highly active antiretroviral therapy (HAART) has markedly improved the prognosis 
of HIV-infected patients1. Nevertheless, HAART can fail for various reasons, including poor 
adherence to therapy, toxicity, drug-drug interaction, or resistance development. Therefore, 
the role of therapeutic drug monitoring (TDM) in the management of antiretroviral drugs is a 
topic of increasing interest2-6. 
TDM has been proposed as a useful tool for the optimization of antiretroviral therapy, 
allowing an effective drug concentration for each individual treated. Drug concentration 
measurements of protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors 
(NNRTIs - applied to individualize drug dosing) are performed in a growing number of 
laboratories. To alert laboratories to undetected problems concerning their assays, our 
department has initiated an International Interlaboratory Quality Control Program for TDM in 
HIV infection (QC-program)7;8. The participating laboratories analyzed samples containing 
different concentrations of PIs and NNRTIs. However, not only is the accurate measurement 
of the drug concentration important, an expert interpretation of the concentration is absolutely 
critical in understanding what the results actually mean. 
To observe whether the expert recommendations concerning dose adjustments, adherence, 
time interval between drug doses, and interaction between different drugs are comparable, 
the third round of the QC-program consisted of the analysis not only of plasma samples 
containing antiretroviral drugs but also of patient cases. The results of the analysis of the 
plasma samples have been reported previously8. The main outcome of the 30 participating 
laboratories that reported their results, were as follows: 82% of all measurements were 
performed within 80%-120% accuracy limits. Only 3 laboratories performed all their 
measurements within these limits; 12 participants reported at least 90% of their analyses as 
within the acceptance range, and the mean accuracy for low drug concentrations was worse 
than that for medium and high concentrations. The percentage of satisfactory measurements 
from the 6 laboratories participating for the third time in the QC-program increased from 54% 
in the first round to 85% in the third round. 
The case was sent to all 30 participants of the QC-program. The results of this case are 
presented here. 
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METHODS 
 
Case Description 
The case was composed of different topics related to the TDM of antiretroviral drugs. The 
case consisted of a total of 3 parts and the participants were asked to give their advice at the 
end of each part. Patient A was an imaginary patient. Although multiple HIV drugs were 
prescribed for the patient, only plasma levels of PIs (nelfinavir and indinavir) and the NNRTI 
nevirapine were given in this case because PIs and NNRTIs satisfy many criteria for 
therapeutic drug monitoring, whereas nucleoside reverse transcriptase inhibitors are not 
suitable candidates for TDM9. Until now, it has not been established which pharmacokinetic 
parameter (e.g. minimum plasma concentration, maximum plasma concentration) should be 
monitored. In routine clinical care it is often difficult to draw a blood sample at a strictly 
defined time point; therefore, concentration ratios were used to judge the plasma levels of 
the PIs. The concentration ratio represents the measured plasma concentration compared 
with the time-adjusted average concentration, as measured in a reference population of HIV-
infected individuals10. For nelfinavir and indinavir, a minimum concentration ratio is known 
below which virological failure is more likely to occur.  
Patient A has started treatment with stavudine (40 mg twice daily), lamivudine (150 mg twice 
daily), and nelfinavir (1,250 mg twice daily). Viral load was 100,000 copies at the start of 
treatment, but rapidly decreased to undetectable levels at subsequent visits. The patient 
complains of diarrhea, which does not respond to loperamide. The HIV specialist treating 
patient A is concerned about subtherapeutic nelfinavir plasma levels because of the diarrhea 
and orders TDM for nelfinavir. A plasma sample is taken at 10 AM, 2 hours following the 
previous dose of nelfinavir. The nelfinavir plasma level is 3.5 mg/L.  
Question 1 what is your advice? 
 
Nelfinavir is stopped due to the diarrhea and the patient is switched to indinavir 800mg three 
times daily. The diarrhea disappears two days after the change, and the viral load remains 
undetectable. After 4 months without problems, the patient begins to complain of 
parasthesias in his arms and legs. He calls his general practitioner, who prescribes 
carbamazepine at a dose of 200 mg twice daily. Two months later, the patient visits his HIV 
specialist and tells him that the neuropathy has not been resolved. Additionally, his viral load 
has increased to 6000 copies/mL. Because of the toxicity that patient A is suffering from, the 
HIV specialist suspects noncompliance and orders TDM for indinavir. A plasma sample taken 
4 hours after intake of indinavir contains 0.40 mg/L. 
Question 2 what is your advice? 
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Because patient A has an insufficient virological response to the regimen, he is switched to a 
regimen containing zidovudine 300 mg twice daily, didanosine 400 mg once daily, and 
nevirapine 200 mg twice daily. After a few months, the neuropathy decreases, and 
carbamazepine is discontinued. Two months later, the viral load is 30,000 copies/mL. TDM 
for nevirapine is ordered 4 weeks later to rule out suboptimal plasma levels. The nevirapine 
plasma level taken 8 hours after intake is 2.9 mg/L. 
Question 3 what is your advice? 
 
The laboratories participating in rounds 1 and 2 of the QC-program were invited to participate 
in round 3. In addition, participants were recruited by sending emails to authors who reported 
methods for analyzing protease inhibitors nevirapine or efavirenz. Furthermore, participants 
contacted our department after the results of the first round of the QC-program were 
reported7. 
In rounds 1, 2 and 3, totals of 7, 18, and 30 laboratories participated, respectively. Round 3 
was the first round in which a case was sent to the participants of the QC-program. 
 
 
RESULTS 
 
Results of the case were received from 16 of 30 participants who analyzed the plasma 
samples of the QC-program. The respondents analyzed 286 samples, 255 (86%) of which 
were within the acceptable limits of 80%-120% and the nonrespondents to the case analyzed 
228 out of 278 (82%) within the acceptable range. 
Three of the respondents were from the United States or Canada, and the other 13 from 
Europe. Of the total number of 16 respondents, 1 was working at a commercial laboratory, 
and 15 worked in university hospitals, all at the Department of Clinical Pharmacy of 
Pharmacology. Ten respondents were pharmacists and 6 were physicians. Of the 
respondents, the majority (14 out of 16) regularly published articles concerning 
pharmacokinetics and TDM of antiretroviral drugs and interaction studies with antiretroviral 
drugs in leading journals, whereas only 3 out of 14 of the nonrespondents did so.  
Of the 14 participating laboratories that measured the plasma samples but did not return 
answers to the case, 1 participant reported not offering clinical advice. Thirteen laboratories 
did not give a reason for not responding to the case.  
 
QUESTION 1 
The therapeutic level of nelfinavir is found to be 3-4 mg/L 2 hours postdose11. Furthermore, a 
nelfinavir concentration ratio of less than 0.90 detects virological failures12. In Figure 1A, the 
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population curve of nelfinavir, together with the line representing the 0.90 concentration ratio, 
are presented. The nelfinavir level of patient A was adequate. Of the 16 respondents, 14 
reported that the nelfinavir plasma level was sufficient, 1 found the level higher than 
expected, and 1 did not give any comment on the level. 
Diarrhea is a known side effect of nelfinavir, which was noted by 4 participants. Hsyu et al13 
reported that the presence of diarrhea did not correlate with plasma nelfinavir concentrations 
or efficacy, although it is a common side effect of nelfinavir: 91% of the patients in the 
nelfinavir study of Elion14 experienced a mild grade of diarrhea. Because the nelfinavir 
plasma level is not influenced in patients with diarrhea, it does not seem reasonable to adjust 
the dose of nelfinavir. Furthermore, 2 respondents recommended taking opium tincture or 
calcium supplements to treat the diarrhea, even though the diarrhea persisted during use of 
loperamide. Loperamide is a powerful drug against diarrhea, so changing this to opium 
tincture does not seem to be a logical step, although calcium supplements may help15. 
Several respondents advised to determine the Cmin and/or the nelfinavir hydroxy metabolite 
M8 (M8) and reducing the dose if concentrations were sufficient. The nelfinavir level is 
therapeutic, so there would be no need to remeasure nelfinavir or to adjust the dose. 
Finally, 8 respondents (50%) advised switching from nelfinavir to another PI if the diarrhea 
persisted.  
Advice: Switch from nelfinavir to another PI. 
 
QUESTION 2 
An indinavir concentration ratio of less than 0.75 detects virological failures, and an indinavir 
level of 0.40 mg/L 4 hours postdose is low16-18 (Fig. 1B). This was reported by 15 of the 16 
respondents. With regard to the compliance of the patient, 7 respondents reported having 
doubts about the compliance, whereas 2 reported that they believed that the patient was 
compliant. One respondent reported that he did not think that the patient was compliant.  
Aside from noncompliance, an interaction with carbamazepine might offer an 
explanation for the low indinavir level. All 16 participants noted this. Carbamazepine is a 
potent enzyme inducer of the CYP3A4 enzyme system, and protease inhibitors, such as 
indinavir, are substrates for and inhibitors of CYP3A4. So, carbamazepine may stimulate the 
metabolism of indinavir19, leading to low indinavir levels and possible therapy failure20. 
Three respondents suggested giving the patient a low dose of ritonavir to neutralize the 
effect of carbamazepine on the low indinavir level. In such cases, the physician must pay 
extra attention because there can be possible interactions between ritonavir and 
carbamazepine, as well, leading to carbamazepine toxicity21;22. One respondent noted this. 
Ritonavir is a highly potent inhibitor of CYP3A4 and is found to interfere with carbamazepine 
within 12 hours of administration, leading to elevated carbamazepine levels22. 
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Figure 1: A: Nelfinavir plasma concentrations (solid line), as a function of time after the last 
ingestion of nelfinavir. The curve was constructed on median values of 618 plasma 
concentrations obtained from 355 patients. The concentration ratio limit of 0.90 is marked by 
the dashed line. The concentration of patient A question 1 is reflected by ■. B: Indinavir 
plasma concentrations (solid line), as a function of time after the last ingestion of indinavir. 
The curve was constructed on average pharmacokinetic curves of 14 subjects. The 
concentration ratio limit of 0.75 is marked by the dashed line. The concentration of patient A 
question 2 is reflected by ■.  
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Instead of adding a further drug interaction, a more reasonable suggestion could be to switch 
the carbamazepine to another drug, as suggested by 6 respondents. The drugs 
recommended were gabapentine, valproate, amitryptiline, clonazepam, and imipramine. 
Valproate seems somewhat controversial because it has been shown to stimulate the viral 
replication of HIV-1 in vitro23;24. 
The use of anticonvulsants, such as gabapentin and tiagabine, may be most appropriate in 
patients undergoing concurrent protease inhibitor therapy25. 
Three respondents suggested switching indinavir to another antiretroviral drug that does not 
interact with carbamazepine. This is probably not a correct recommendation, because 
carbamazepine did not resolve the neuropathy. Neuropathy is an adverse event of 
stavudine26. Switching stavudine to zidovudine (as suggested by 2 respondents) may not be 
the right advice, because of the possible cross-resistance between these 2 drugs. Lowering 
the dose of stavudine, as reported by 1 respondent, should not be considered. Only patients 
with a low body weight can be given a low dose of stavudine. The weight of the patient in this 
case is not specified. 
The suggestion to test resistance before changing therapy was made on 2 occasions by 
respondents, which is a good recommendation. Youree and D’Aquila27 reported that an 
increasing amount of data indicates that antiretroviral resistance testing may improve the 
response to therapy and increase the likelihood of achieving viral suppression. 
Advice: After resistance testing, switch carbamazepine to another drug or switch therapy. 
 
QUESTION 3 
One of the 16 respondents did not answer question 3, because of a lack of experience with 
nevirapine. 
Six respondents reported that the nevirapine level was too low or subtherapeutic, whereas 9 
reported that the nevirapine level was low. The trough concentration should be above 3.4 
mg/L6;28-31 or above 3.0 mg/L, according to Vries-Sluijs et al32. A patient who has a level of 
2.9 mg/L at 8 hours after intake will probably have a trough level even lower than this. Five 
respondents suggested increasing the dose of nevirapine. It is not the most obvious advice, 
because of the interaction of nevirapine and carbamazepine, which could occur in the first 
months after changing the regimen of this patient. Carbamazepine may stimulate the 
metabolism of nevirapine, leading to low nevirapine levels, which in turn result in resistance 
to nevirapine. None of the respondents noted this, although 6 respondents wondered 
whether resistance existed or advised performing resistance testing. This seems to be the 
most suitable choice.  
Advice: After resistance testing, change regimen. 
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Table 1 presents the score per question of the respondents for the judgment of the drug level 
and the recommendations. It is very clear that it is more difficult to give correct advice than to 
judge the drug level. 
 
Table 1: Score per question 
 Good interpretation of drug 
level  
Correct recommendation 
 N % N % 
Question 1 14/16 88 8/16 50 
Question 2 15/16 94 7/16 44 
Question 3 15/16 94 6/16 38 
Overall 43/48 92 21/48 44 
 
 
DISCUSSION 
 
Recommendations given by the respondents were in part not comparable. This study 
revealed that it was more complicated to report a satisfactory recommendation than to judge 
the drug level correctly, these tasks having success rates of 44% and 92% respectively. 
Some of the respondents did not give a recommendation or advice as requested but rather 
made an analysis of the case. They judged only the drug levels and mentioned the 
interaction between indinavir and carbamazepine without giving advice. For questions 1-3, 
respectively, 6, 3, and 5 respondents did not give any advice. 
Furthermore, part of the advice for question 2 was to order resistance testing (2 participants). 
For question 3, the same 2 respondents again advised resistance testing, as did 2 other 
respondents. A number of studies are performed to assess the virologic and immunologic 
impacts of resistance testing. Considerable data from retrospective and prospective studies 
now support the use of HIV resistance testing33-38. To date, there is no unanimity as regards 
whether to use genotypic or phenotypic resistance assays. Both assays have their relative 
advantages and relative limitations35. Only 1 of the 4 respondents who suggested resistance 
testing specifically advised ordering genotype resistance testing without a stated logical 
reason. Nevertheless, resistance testing is increasingly becoming a basis for choosing the 
right regimen. 
The judgment of the antiretroviral levels did not cause any trouble, as 14, 15, and 15 
respondents out of a total of 16 were able to do so correctly for questions 1, 2, and 3, 
respectively, the success rates being 88%, 94%, and 94 % for these (Table 1). On the other 
hand, giving an acceptable recommendation was more complicated. For questions 1, 2, and 
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3, only 50%, 44%, and 38% of the respective respondents reported satisfactory 
recommendations. These percentages may have been different if the remaining 16 
respondents had reported answers for the case. The results measuring the plasma samples 
of the respondents and non-respondents to the case were comparable, the acceptable 
results reaching totals of 86% and 82% respectively. Four of the 16 respondents reported 
correct recommendations for all 3 questions (data not shown).  
The authors believe that TDM represents not only therapeutic drug measuring, but also 
therapeutic drug monitoring. Therapeutic drug measuring is only one part of TDM. Expert 
interpretation of a drug concentration is essential to ensure a full clinical benefit. Expert 
advice cannot be given without knowledge of the history of previous antiretroviral treatments, 
the concomitant medications, patient adherence to its treatment, the results of resistance 
testing in case of failure, and the correct drug level. Therefore, the authors are of the opinion 
that TDM should be a multidisciplinary function, where collaboration is needed among 
scientists, clinicians, nurses, and pharmacists. 
 
In conclusion, the recommendations reported by the respondents are in part not comparable. 
On average, almost half of the recommendations given were correct. The variation in 
recommendations may result in implications for the patient. For example, wrong dose 
adjustments may occur, which may lead to resistance development. Therefore, the QC-
program is of use to alert participants that TDM of antiretroviral drugs is a complex matter. 
The authors believe that it is of great importance that health professionals are kept well 
informed about the latest developments concerning TDM. 
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Antiretroviral therapy can decrease the amount of HIV-1-RNA in blood plasma and in 
semen1. However, the decline of the HIV-1-RNA concentration and the evolution of virus in 
semen during therapy can show discordance with blood plasma, indicating viral 
compartmentalization2;3. Poor penetration into the male genital tract by some antiretroviral 
drugs can contribute to the different viral dynamics in this compartment4.  
Data available on drug concentrations in semen show that the penetration of the protease 
inhibitors (PI) nelfinavir, ritonavir, and saquinavir is poor5. The nucleoside analogues 
zidovudine, stavudine, lamivudine and abacavir, the nonnucleoside reverse transcriptase 
inhibitors nevirapine and efavirenz, and the PIs indinavir and amprenavir penetrate well into 
the male genital tract3 6-12. There are no data on the penetration of the PI lopinavir into the 
male genital tract.  
 
HIV-1-infected men who were on a lopinavir containing regimen for a minimum of 4 weeks 
were recruited from our HIV outpatient clinic. The patients had to have no signs or symptoms 
of a genital infection. Semen samples were obtained by masturbation, centrifuged between 2 
and 4 hours after collection at 1200 g for 10 minutes to obtain seminal plasma and stored at 
–70°C until analysis. Within 2 hours after semen collection, a blood sample was taken for the 
measurement of the blood plasma lopinavir and HIV-1-RNA concentrations.  
The local Medical Ethics Committee approved the study, and written informed consent was 
obtained from all patients. 
 
HIV-1-RNA in EDTA plasma was measured using the quantiplex bDNA assay (Bayer 
Corporation, Diagnostics Division, Emeryville, CA, USA), with a lower limit of quantification 
(LLQ) of 50 copies/mL. 
HIV-1-RNA in seminal plasma was measured using the ultra Nuclisens HIV-1 QT assay 
(Organon Teknika, Boxtel, The Netherlands), with a LLQ of 50 copies/mL. 
Lopinavir concentrations in heparinized blood plasma and in seminal plasma were measured 
using a high-performance liquid chromatographic (HPLC) procedure13. The intraday and 
interday variation of this assay was less than 5%. 
Fourteen patients on a lopinavir containing regimen for a median of 16 weeks (range 4 – 41 
weeks) were included in this study. Lopinavir was started in 9 of the patients because of 
virological failure on their previous antiretroviral regimen and in 5 because of side effects of 
their previous regimen.  
The 5 patients who switched therapy because of side effects had an undetectable HIV-1-
RNA in blood plasma at the moment of switching therapy. At the time the study samples 
were taken all 5 patients still had an undetectable HIV-1-RNA in blood plasma and an 
undetectable HIV-1-RNA in seminal plasma. 
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Figure 1: Lopinavir concentrations in (a) blood plasma and (b) seminal plasma versus time 
after intake. O Detectable HIV-1-RNA levels in blood plasma; ● Undetectable HIV-1-RNA 
levels in blood plasma and seminal plasma. (c) Ratio of the concentration of lopinavir in 
seminal plasma and blood plasma 
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Of the 9 patients starting lopinavir because of virological failure, 4 had a detectable HIV-1-
RNA in blood plasma at the time the study samples were taken. These patients were not yet 
in a steady-state, and during follow-up their blood plasma HIV-1-RNA further decreased. 
Only 1 of these 4 patients had an undetectable HIV-1-RNA in seminal plasma. The other 5 
patients starting lopinavir because of virological failure had an undetectable blood plasma 
HIV-1-RNA. One of these patients had a detectable HIV-1-RNA in seminal plasma. 
 
In 5 of the 14 patients the blood plasma concentration of lopinavir was below the desired 
concentration of 5.0 mg/L (Abbott product information). The other 9 patients had a plasma 
concentration > 5.0 mg/L (Fig. 1A). 
The lopinavir concentration in seminal plasma ranged between 0.046 and 3.9 mg/L (median 
0.23 mg/L, IQR 0.15-0.33). No relationship was found between the lopinavir concentration in 
seminal plasma and the time since medication intake (ρ = 0.22, p=0.45; Spearman’s rank) 
(Fig. 1B). There was a weak relationship between the blood plasma and the seminal plasma 
concentration (ρ = 0.51, p=0.07;Spearman’s rank). The median ratio of the concentrations of 
lopinavir in seminal plasma and in blood plasma was only 0.034 (IQR 0.021-0.070) (Fig. 1C). 
There was no relationship between the lopinavir concentration in blood plasma or seminal 
plasma and HIV-1-RNA blood plasma or in seminal plasma (ρ =0.11, p=0.73; Spearman’s 
rank) (Fig. 1A and 1B) and no relationship between the lopinavir concentration in seminal 
plasma and HIV-1-RNA in seminal plasma (ρ=0.46, p= 0.11; Spearman’s rank). 
We demonstrated that lopinavir has a poor penetration into the seminal plasma, with a 
median concentration of only 0.23 mg/L (range 0.046-3.9 mg/L), assuming the same 
percentage protein binding in seminal plasma as in blood plasma (98-99%; Abbott product 
information).  Because of this poor penetration one would expect a poor suppression of the 
viral replication in semen. However, only 4 out of the 14 patients had a detectable HIV-1-
RNA in seminal plasma of which 3 patients were not yet in a steady-state. An explanation for 
this could be that all patients were on a regimen containing at least one other antiretroviral 
drug with a good penetration into the seminal plasma (data not shown). It is, however, 
conceivable that the replication of HIV-1 in the genital tract of our patients is only partially 
suppressed by the other drugs of the regimen, usually 2 nucleoside analogues. Although 
most of the patients had an undetectable HIV-1-RNA level in seminal plasma, the median 
time on lopinavir was only 16 weeks, and it is possible that in time there will be a selection of 
HIV-1 strains resistant for the other drugs used. There are indications that the selection of 
resistant HIV-1 strains in the male genital tract can differ from that in blood plasma14. If 
resistant HIV strains migrate to other compartments a patient is at risk for systemic 
virological failure. Resistant strains in seminal plasma may also lead to the infection of other 
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persons with resistant strains. A longer follow-up of HIV-1-RNA in seminal plasma is 
necessary to be confident that selection of resistance mutations is not a risk of regimens with 
only partial penetration into the male genital tract. 
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ABSTRACT 
 
Tenofovir disoproxil fumarate (tenofovir DF) was studied in combination with rifampin in 24 
healthy subjects in a multiple-dose, open-label, single-group, two-period study. All subjects 
were given tenofovir DF at 300 mg once a day from days 1 to 10 (period 1). From days 11 to 
20 the subjects received tenofovir DF at 300 mg combined with rifampin at 600 mg once 
daily (period 2). The multiple-dose pharmacokinetics of tenofovir (day 10 and 20) and 
rifampin (day 20) were assessed. The drug-related adverse events (AEs) experienced during 
this study were mostly mild. Only one grade 3 AE possibly or probably related to the 
treatment (raised liver enzyme levels) occurred during period 2; the subject was withdrawn 
from the study. Pharmacokinetic data for 23 subjects were thus evaluable. Point estimates 
for the mean ratios of tenofovir with rifampin versus tenofovir alone for the area under the 
concentration-time curve from zero to 24h (AUC0-24), the maximum concentration of drug in 
plasma (Cmax), and the minimum concentration of drug in plasma (Cmin) were 0.88, 0.84, and 
0.85 respectively. The 90% classical confidence intervals for AUC0-24, Cmax, and Cmin were 
0.84 to 0.92, 0.78 to 0.90, and 0.80 to 0.91, respectively, thus suggesting pharmacokinetic 
equivalence. Similarly, coadministration of rifampin and tenofovir DF did not result in 
changes in the values of the tenofovir pharmacokinetic parameters. For rifampin, the values 
of the pharmacokinetic parameters found in this study were comparable to those found in the 
literature, indicating that tenofovir DF has no effect on the pharmacokinetics of rifampin. In 
conclusion, adaptation of either the rifampin or tenofovir DF dose for the simultaneous 
treatment of tuberculosis and human immunodeficiency virus (HIV) infection in HIV-infected 
patients is probably not required. 
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INTRODUCTION 
 
Co-infection with Mycobacterium tuberculosis and human immunodeficiency virus (HIV) is 
frequent, particularly in Africa and Asia1-3. Simultaneous treatment of tuberculosis and HIV-
infection may lead to complex combination therapy. Rifampin is a drug of choice for the 
treatment of tuberculosis. Rifampin is known to have major pharmacokinetic interactions with 
HIV protease inhibitors and nonnucleoside reverse transcriptase inhibitors4-9. Tenofovir 
disoproxil fumarate (tenofovir DF) is the first drug from a new class of anti-HIV agents 
(nucleotide reverse transcriptase inhibitors) that has been recently approved for use for the 
treatment of HIV-infection in adults. However, no data are available regarding its 
pharmacokinetics in combination with tuberculostatic drugs, in particular, rifampin. No 
influence of rifampin on the pharmacokinetics of tenofovir is expected, because both drugs 
are metabolized and eliminated in different ways. Tenofovir is eliminated unchanged by 
glomerular filtration and active tubular secretion10;11, while rifampin is extensively metabolized 
by intestinal and hepatic metabolism12. However, pharmacokinetic interaction cannot be 
excluded. 
This clinical trial described here was designed to explore the pharmacokinetics of tenofovir 
DF with and without rifampin in an effort to establish whether there is a need to adjust the 
dosage of either medication when the two medications are used for the treatment of patients 
coinfected with M.tuberculosis and HIV. 
 
 
MATERIALS AND METHODS 
 
Study Design 
The present study was designed to evaluate the effect of 600 mg of rifampin on the 
pharmacokinetics of 300 mg of tenofovir DF and also to assess whether tenofovir DF has a 
substantial impact on steady-state exposure to rifampin. This study was a multiple-dose, 
open-label, single-group, two-period study with 24 healthy volunteers. First, the subjects 
received tenofovir DF at 300 mg once daily for 10 days (period 1). At study day 10, a steady-
state 24-h pharmacokinetic curve was obtained for tenofovir. During the second period of the 
study (period 2), tenofovir DF at 300 mg was combined with rifampin at 600 mg once daily, 
again for 10 days. At study day 20, 24-h steady-state pharmacokinetic curves were obtained 
for tenofovir and rifampin. During the study both tenofovir DF and rifampin had to be taken 
with breakfast. On the days prior to study days 9 and 19, the subjects reported to the study 
center for direct observation of dosing with the medications with a standardized breakfast. 
Subsequently, on the evenings of study days 9 and 19 the subjects remained at the study 
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center for 2 overnight stays and remained at the study center until the mornings of study 
days 11 and 21, respectively. On days 9, 10, 11, 19, and 20 the subjects received a 
standardized breakfast of 550 kcal (two slices of white bread, 15 g low fat margarine, 14 g 
jelly, 150 mL orange juice and 150 mL skim milk). The medication was administered 
immediately after breakfast with 200 mL of tap water. All other meals and snacks on the 
pharmacokinetic study days were also standardized. When the subjects took the medication 
at home, study drugs were administered with breakfast (at least two and at most three slices 
of wheat bread). 
No crossover design was used in this study, because rifampin could lead to considerable 
carryover effects, due to its long-lasting cytochrome P450-inducing effect. To eliminate this 
effect a longer washout period would be necessary, but this would have significantly 
prolonged the duration of the study and would have led to difficulties with subject recruitment 
and retention. This study was reviewed and approved by the independent ethics committee 
Arnhem-Nijmegen. Written informed consent was obtained from each study subject prior to 
the conduct of any study related activity. 
 
Study subjects 
Twenty-four healthy male and female subjects were eligible for inclusion in the study. The 
subjects could be between 18 and 65 years of age with a body weight of at least 50 kg and in 
a good age-appropriate health condition, as established by the individual’s medical history; a 
physical examination; electrocardiography; and the results of biochemistry, hematology and 
urinalysis within the 3 weeks prior to administration of the first dose. Other inclusion criteria 
were an ability to sign informed consent voluntarily and a willingness to refrain from the use 
of contact lenses during treatment with rifampin. Exclusion criteria were as follows: positive 
tests for HIV, hepatitis B virus, or hepatitis C virus; a tuberculin skin test reaction of more 
than 15 mm or a tuberculin skin test reaction of 1 to 15 mm with a chest X ray with 
abnormalities consistent with tuberculosis; pregnancy; breast-feeding; the lack of adequate 
contraception (e.g., hysterectomy; bilateral tubal ligation; the use of an intra-uterine device, 
total abstinence, or double-barrier methods; or a postmenopausal state for 2 years) among 
female subjects of childbearing potential; a creatinine clearance rate < 60 mL/min; or a 
serum creatinine level above 133 µmol/L. 
 
Sampling for pharmacokinetic studies 
For determination of the tenofovir and rifampin concentrations in blood plasma, samples of 5 
mL blood, recovered to obtain at least 2 mL of plasma, were collected in heparinized hard 
plastic tubes at the following times: just before drug intake (predosing); on day 10 and day 
20; and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24 h after drug intake. The blood samples were 
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centrifuged at 2,500 x g for 10 minutes at 4°C. The plasma was divided into equal portions, 
transferred to polypropylene tubes, and stored at ≤ -18°C for samples containing tenofovir 
and ≤ -70°C for samples containing rifampin. 
 
Safety 
Blood samples for serum biochemistry analyses, including tests for glucose and 
hematological analyses, and urine samples for urinalysis were taken on study days 1, 4, 9, 
11, 15, 19, and 21. These samples were taken while the subjects were in a fasting condition. 
In females of childbearing potential, testing of blood for human chorionic gonadotropin was 
performed at the screening visit and on study days 11 and 21. An instant test of urine for 
human chorionic gonadotropin was performed on study day –1. To avoid possible 
interactions between drugs of abuse and study drugs, a urine drug screen was performed at 
the screening visit and on study days –1, 9, and 19 with the Instacheck™ Multi-Drug Screen 
panel (Forefront Diagnostics, San Diego, Calif.). Vital signs for cardiovascular safety (systolic 
and diastolic blood pressure and heart rate) were monitored, and an electrocardiogram was 
recorded at the screening visit. The medical and nursing staff of the trial center monitored the 
subjects for adverse events (AEs) throughout their confinement. Subjects voluntarily reported 
any AE or reported AEs in response to general questioning. All AEs occurring between the 
first intake of the trial medication(s) and the end of the trial were reported. The relationship of 
the trial drug(s) was not related or unlikely to be related to the trial drug(s) if evidence existed 
that the AE had a source other than the trial drug(s). AEs were recorded as possibly or 
probably related to the trial drug(s) if a temporal relationship existed between the event onset 
and administration of the trial drug(s) and there was no evidence of an alternative cause for 
the event. 
The severity of the AEs were recorded and graded according to the common toxicity criteria 
(grade: 1, 2, 3, and 4) of the National Institute of Allergy and Infectious Diseases. 
 
Bio-analysis 
Tenofovir concentrations were determined by using a validated high-performance liquid 
chromatography assay with a fluorimetric detector by a modified method13. A Symmetry 
Shield RP18 analytical column (3,5 µm; 150 by 4.6 mm; Waters, Etten-Leur, the 
Netherlands) was used. The method involved extraction of the drug and internal standard, 
adefovir (Gilead Sciences, Foster City, Calif), from 100 µL human plasma by adding 200 µL 
of acetonitrile. The supernatant was evaporated, and 200 µL of 0.34% chloroacetaldehyde in 
50 mM acetate buffer (pH 4.5) was added. Fluorescent compounds were obtained by 40 
minutes of incubation at 90°C. After the samples were cooled at –20°C for 5 minutes, 10 µL 
was injected onto the column. The flow rate was 1 mL/min. The mobile phase consisted of a 
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mixture of phosphate buffer (50 mM; pH 6.8)/acetonitrile (96:4; vol/vol) that resolved the drug 
and the internal standard from endogenous matrix components and other drugs that were 
possibly present. Chromatographic analysis was performed at 30°C under isocratic 
conditions with extinction and emission wavelengths of 232 and 420 nm, respectively. The 
retention times of tenofovir and the internal standard, adefovir, were 6.34 and 3.90 minutes, 
respectively. The concentrations of the quality controls used were 0.03, 0.21, and 1.05 mg/L. 
The intra- and interassay coefficients of variation were less than 4% for all quality controls. 
The lower limit of quantification was 0.0045 mg/L. The rate of recovery of tenofovir from 
human plasma was 86%. 
Rifampin concentrations were determined by using a previously described6 high-performance 
liquid chromatography method. The concentrations of the quality controls used were 2.85, 
9.5, and 24 mg/L. The intra- and interassay coefficients of variation were less than 1.1% for 
all quality controls. The lower limit of quantification was 0.50 mg/L. Samples of the same 
subjects were analyzed by use of the same standard curve. 
 
Pharmacokinetic analysis 
Pharmacokinetic parameters for tenofovir and rifampin were calculated by noncompartmental 
methods by use of the WinNonlin software package (version 4.1; Pharsight Corporation, 
Mountain View, Calif.) and the log/linear trapezoidal rule. On the basis of the individual 
plasma concentration-time data, the following pharmacokinetic parameters were determined: 
the area under the plasma concentration-time curve (AUC) from time zero to 24 h (AUC0-24; 
in milligram.hour per liter), the maximum concentration of drug in plasma (Cmax; in milligrams 
per liter), the time to reach Cmax (Tmax; in hours), the minimum concentration drug in plasma 
(Cmin; in milligrams per liter), the apparent elimination half-life (t1/2; in hours), and the apparent 
oral clearance (CL/F; in liters per hour). AUC0-C*, where C* is the last quantifiable 
concentration, was calculated for rifampin. Cmin and CL/F were not calculated for rifampin. 
 
Statistical analysis 
Statistical analyses were performed with SPSS software (version 11.0; SPSS Inc. 1989 to 
1999). Descriptive statistics were calculated with Excel 2000 software (Microsoft Corporation 
1985 to 1999). Evaluation of the AUC0-24 and the Cmax of tenofovir was the main objective of 
this trial. These parameters are considered the primary characteristics for the extent and the 
rate of drug absorption, respectively. The bioequivalence of tenofovir was determined by 
comparing the values of the relevant pharmacokinetic parameters obtained with the test 
treatment (tenofovir DF and rifampin on study day 20) to those obtained with the reference 
treatment (tenofovir DF alone on study day 10) by using the following statistical methods. 
The AUC0-24, Cmax, and Cmin of tenofovir were reported for study day 10 and study day 20 
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together by use of the ratios of the values on study day 20/values on study day 10. The 
arithmetic means and standard deviations are given for study day 20 and study day 10. The 
geometric mean ratios and 90% classical confidence intervals for AUC0-24, Cmax, and Cmin 
were calculated. Treatments were considered bioequivalent if the respective 90% classical 
confidence intervals for AUC0-24 and Cmax were included within the bioequivalence range of 
80% to 125%14. The values of the pharmacokinetic parameters for rifampin were compared 
with data from literature by the use of descriptive statistics. The study was powered for the 
tenofovir Cmax by using nQuery software, and a sample size of 15 was required to achieve an 
80% power to reject the null hypothesis that the two treatments are not equivalent in favor of 
the alternative hypothesis that the means of the two treatments are equivalent, when the 
expected difference is 0.000. By this approach, a sample size of 15 would provide a 93% 
power for AUC0-24. By considering the possibility that the subjects would drop out and/or that 
some difficulties with sample or pharmacokinetic analysis with some subjects would occur, 
24 subjects were enrolled in this study. 
 
 
RESULTS 
 
Demographics 
Twenty-four subjects (13 males, 11 females) were enrolled in this trial. One male subject was 
black; all other subjects were Caucasian. The mean age of the subjects was 41 years (range, 
20 to 63 years). The mean body weight was 77 kg (range, 58 to 97 kg), and the mean height 
was 1.75 m (range, 1.59 to 1.88 m). 
 
Pharmacokinetics 
The pharmacokinetic evaluation was based on data sets for subjects that completed the study 
on both study days (study days 10 and 20). Data for 23 subjects were included in the 
pharmacokinetic analysis of tenofovir and rifampin. Table 1 provides a summary of the values 
of the pharmacokinetic parameters for tenofovir, including the arithmetic means, geometric 
mean ratios, and 90% confidence interval estimates for the pharmacokinetic parameters for 
tenofovir alone (study day 10) and tenofovir in combination with rifampin (study day 20). The 
tenofovir AUC0-24, Cmax, and Cmin were lower in period 2 when tenofovir DF was 
coadministered with rifampin. However, the magnitudes of these differences were small, with 
geometric mean ratios (90% confidence intervals) of 0.88 (0.84 to 0.92), 0.84 (0.78 to 0.90), 
and 0.85 (0.80 to 0.91) for AUC0-24, Cmax, and Cmin, respectively, suggesting pharmacokinetic 
equivalence when tenofovir DF was dosed with or without rifampin.  
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Table 1: Pharmacokinetics of tenofovir 
Parameter Day 10 Day 20 Geometric mean ratio 
day20/day10 and 90% CI  
AUC0-24 (mg.h/L) 
Cmax (mg/L) 
Cmin (mg/L) 
Tmax (h)b 
T
1/2 (h) 
CL/F (L/h) 
3.56 ± 0.77 (3.48)a 
0.36 ± 0.080 (0.36) 
0.071 ± 0.016 (0.069) 
1.0 (1.0-3.0) 
13.8 ± 4.53 (13.2) 
88.1 ± 19.0 (86.2) 
3.11 ± 0.57 (3.06) 
0.30 ± 0.060 (0.30) 
0.060 ± 0.011 (0.059) 
1.0 (1.0-2.0) 
11.6 ± 2.77 (11.2) 
99.8 ± 20.3 (98.0) 
0.88 (0.84-0.92) 
0.84 (0.78-0.90) 
0.85 (0.80-0.91) 
N=23, CI= confidence interval 
a Values are arithmetic means ± standard deviations (geometric means), unless indicated 
otherwise. b Values are medians (ranges) 
 
 
Table 2 Pharmacokinetics of rifampin 
Value on day 20 
(this study) 
(n=23) 
Literature  
(with breakfast) 
(n=14)a 
Tmax (h) 
Cmax (mg/L) 
AUC0-12  (mg.h/L) 
T1/2 (h) 
2.4 (0.6)b 
10.9 (3.0) 
43.27 (15.28) 
1.5 (0.3) 
4.43 (1.11) 
7.27 (2.25) 
50.97 (14.27) 
a The data are from reference 15 and are for subjects who received rifampin with breakfast. 
b Values are means (standard deviations) 
 
 
Figure 1 illustrates the effects of rifampin on the mean concentration-time profiles of 
tenofovir. Table 2 presents the values of the pharmacokinetic parameters for rifampin when it 
was combined with tenofovir and the values of the pharmacokinetic parameters of rifampin 
from literature12;15. The values of the pharmacokinetic parameters of rifampin when it was 
combined with tenofovir are comparable to those in the literature when rifampin is 
administered with food, suggesting that tenofovir has no influence on rifampin exposure. 
 
Safety 
All 24 subjects reported one or more AEs at some time during the study. No subject 
experienced a grade 4 AE or a serious AE. In total, 160 grade 1 or grade 2 AEs were 
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reported. A total of 102 AEs were judged to be possibly or probably related to a study 
drug(s). During treatment with tenofovir DF (period 1), 33 possibly or probably related AEs 
were reported, while during period 2 (tenofovir DF combined with rifampin) 69 possibly or 
probably related AEs were reported. Of the 69 AEs reported during period 2, 24 AEs were 
related only to rifampin. Each subject reported discoloration of the urine. Most of the study-
drug related AEs were mild (85% were grade 1 in severity). All AEs resolved after withdrawal 
of treatment. 
All 24 subjects completed treatment period 1 (tenofovir DF alone). The most common AEs 
that were reported during treatment with tenofovir DF were fatigue, headache and 
gastrointestinal disorders. 
During period 2 one subject was withdrawn from the study due to several complaints, which 
were rash, headaches, abdominal disorders, fatigue, somnolence, and dizziness. The study 
medications were stopped on study day 15. At the follow up visit, 5 days later, the subject 
developed elevated liver enzymes levels, which were judged to be a grade 3 AE. Nine days 
after the first follow-up visit the liver enzyme levels returned to normal. The AEs that occurred 
during the combination treatment with tenofovir DF and rifampin consisted mainly of flu-like 
symptoms (e.g. fatigue, headache and gastrointestinal disorders) and urine discoloration, 
which are well-known AEs of rifampin16. 
No clinically significant hematology or urinalysis values were observed in this study. 
 
 
DISCUSSION 
 
This study was designed to investigate whether rifampin influences the pharmacokinetics of 
tenofovir. The study showed that bioequivalence could be suggested for tenofovir DF 
combined with rifampin and tenofovir DF given alone and that the combination of tenofovir 
DF with rifampin was generally well tolerated, as only one patient prematurely discontinued 
from study. 
The confidence intervals for AUC and Cmin were 0.84 to 0.92 and 0.80 to 0.91, respectively, 
while the confidence interval was 0.78 to 0.90 for Cmax. By definition, bioequivalence was 
proven for AUC and Cmin, but was only suggested for Cmax14. 
The tenofovir DF dose used in this study (300 mg once daily) is the dose recommended for 
the treatment of HIV infection in adults17. The rifampin dose used (600 mg once daily) is an 
accepted regimen for the treatment of tuberculosis in patients weighing more than 50 kg16. 
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A previous study18 has shown that steady-state conditions for rifampin are generally 
achieved after the sixth daily dose of rifampin at 600 mg. To ensure the achievement of 
steady-state pharmacokinetics, subjects were given tenofovir DF combined with rifampin for 
10 days before pharmacokinetic assessment.  
The reason for the lower observed tenofovir levels is unknown. Several mechanisms could 
contribute to this interaction. Because tenofovir is not metabolized and is eliminated 
unchanged by a combination of glomerular filtration and active tubular secretion10;11, it is 
unlikely that the inducing effect of rifampin on hepatic and intestinal cytochrome P450 
enzymes (especially CYP3A4)4 is the mechanism responsible for this effect. This is 
supported by no apparent changes in tenofovir t1/2 and no clinically relevant effects of 
rifampin on the tenofovir Cmin. 
Similarly, as tenofovir minimally binds to proteins in human plasma or serum (< 0.7% and 
7.2% respectively)17, altered distribution is also probably not the mechanism responsible for 
the pharmacokinetic differences observed. As the decrease in tenofovir Cmax was 16% while 
the decrease in AUC0-24 was 12%, the cause may be in the process of tenofovir DF or 
Figure 1: Plasma tenofovir concentrations ■ tenofovir concentration on study day 10 
(n=23) after administration of 300 mg once daily, ♦ tenofovir concentrations on study day 
20 (n=23) after administration of 300 mg combined with rifampin at 600 mg once daily. 
Data are presented as means, and error bars indicate standard deviations 
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tenofovir absorption. Rifampin has been shown to be an inducer of the efflux transporter P 
glycoprotein19. No information exists in the literature that P glycoprotein plays a role in the 
process of absorption of tenofovir in vivo. However, van Gelder et al20 have described the 
transport of tenofovir DF by a P-glycoprotein-related efflux mechanism in the Caco-2 system.  
AEs led to one discontinuation in this study; grade 3 elevations in hepatic enzyme levels 
were reported after the medication was stopped during period 2, when tenofovir DF was 
combined with rifampin. Liver disturbance is a well-known side effect of rifampin. 
Gastrointestinal disorders are well-known AEs of both tenofovir and rifampin and occurred in 
a total of 46% of the study subjects during both study periods. During period 2 all subjects 
reported discoloration of their urine which is a well-known AE of rifampin16.  
Some additional considerations are important for the extrapolation of the results of this study 
to patients. First, it should be noted that all the participants in this study were healthy 
subjects. It cannot be excluded that the pharmacokinetics of tenofovir and rifampin are 
different in HIV-infected patients coinfected with M. tuberculosis due to one or both of the 
diseases. Second, 23 of the 24 subjects of this study were Caucasian. Race might have an 
effect on the values of the pharmacokinetic parameters of tenofovir, although the available 
pharmacokinetic data do not indicate substantial differences with regard to race17. Finally, the 
subjects in this study were given tenofovir DF and rifampin only, while HIV-infected patients 
coinfected with M. tuberculosis are treated with other antiretroviral and tuberculostatic drugs, 
which can cause interactions. 
 
In conclusion, the data from this study demonstrate that the addition of rifampin to tenofovir 
DF is well tolerated, and the small decrease in plasma tenofovir levels during combination 
treatment suggests that these drugs can be coadministered without the need for dose 
adjustments. This implies that standard doses should be a starting point for using these 
medications in HIV-infected patients. Additional pharmacokinetic studies in a clinical setting 
are warranted to confirm the findings of this study. 
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ABSTRACT 
 
Introduction: Tenofovir disoproxil fumarate (DF) has been studied in combination with 
efavirenz in healthy volunteers and no interaction was found. No data are available on the 
possible interaction of tenofovir DF with nevirapine and efavirenz in HIV-infected patients. In 
this study the combination of nevirapine 200 mg twice daily with tenofovir DF 300 mg once 
daily and nevirapine 400 mg once daily with tenofovir DF 300 mg once daily were compared 
with nevirapine twice daily or once daily without tenofovir DF in HIV-infected patients. 
Furthermore, the combination of efavirenz 600 mg and tenofovir DF 300 mg once daily was 
compared with use of efavirenz 600 mg once daily only. 
Methods: Data were retrospectively collected from routine therapeutic drug monitoring plasma 
samples. Nevirapine, efavirenz, tenofovir plasma levels, and tenofovir concentration ratios 
were analyzed. The concentration ratio represents the measured plasma concentration 
compared with the time-adjusted average concentration, as measured in a reference 
population. Six different groups were studied: 200 mg nevirapine twice daily, 400 mg 
nevirapine once daily, 600 mg efavirenz once daily, all without tenofovir DF (group 1, 2, and 3, 
respectively), and the same groups combined with tenofovir 300 mg once daily (group 4, 5, 
and 6, respectively). 
Results: Plasma samples were evaluable for 272, 18, 126, 32, 94, and 118 patients in the 
groups 1-6 respectively. No differences were found in plasma levels for tenofovir, nevirapine, 
and efavirenz for either of the combinations studied. Addition of tenofovir DF to efavirenz or 
nevirapine in HIV-infected patients does not influence the plasma levels of nevirapine or 
efavirenz. Furthermore, nevirapine and efavirenz have no effect on tenofovir plasma levels 
and tenofovir concentration ratios. 
Conclusion: Efavirenz or nevirapine can be coadministered with tenofovir DF in HIV-infected 
patients without dose modifications. 
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INTRODUCTION 
 
Current treatment of patients with human immunodeficiency virus (HIV) infection involves the 
use of highly active antiretroviral therapy regimens, which generally comprise at least 3 drugs 
belonging to at least 2 of the currently available antiretroviral classes1. Tenofovir disoproxil 
fumarate (DF) is the first drug from a new class of HIV agents (nucleotide reverse 
transcriptase inhibitors) that is approved for use in the treatment of HIV infection in adults2. 
Because tenofovir is not metabolized but eliminated unchanged by a combination of 
glomerular filtration and active tubular secretion3;4 and tenofovir does not inhibit drug 
metabolism mediated by any of the following CYP450 isoforms: CYP3A4, CYP2D6, CYP2C9, 
or CYP2E12, it was thought not likely to cause interactions with other HIV agents. Although 
tenofovir is not involved in clinically significant drug-drug interactions with the majority of other 
antiretrovirals and frequently used other medications in HIV-infected patients, there are a few 
notable exceptions. Unexpectedly, tenofovir has been found to increase plasma exposures of 
didanosine, putatively via inhibition of its metabolism by purine nucleoside phosphorylase; 
reducing the didanosine dose from 400 mg once daily to 250 mg once daily in patients 
weighing more than 60 kg is recommended during concomitant use. In addition, tenofovir has 
been shown to decrease atazanavir plasma levels in pharmacokinetic studies in healthy 
subjects via an unknown mechanism; use of ritonavir-boosting (atazanavir 300 mg with 100 
mg of ritonavir) is recommended during concomitant use. 
Of the nonnucleoside reverse transcriptase inhibitors, efavirenz was studied in combination 
with tenofovir DF in healthy volunteers5. Although there was no effect of tenofovir DF on the 
pharmacokinetics of efavirenz and no alterations in the pharmacokinetics of tenofovir were 
observed, it is prudent to confirm the absence of a drug-drug interaction between tenofovir DF 
and efavirenz in HIV-infected patients. In addition, no data are currently available regarding 
the pharmacokinetics of another nonnucleoside reverse transcriptase inhibitor, nevirapine, in 
combination with tenofovir DF. Possible interactions between tenofovir and nevirapine or 
efavirenz could involve decreased or increased level of one of the drugs, resulting in 
subtherapeutic concentrations or toxic concentrations of the antiretroviral drugs, respectively. 
One useful mechanism to assess potential drug-drug interactions is through exploration of 
large therapeutic drug monitoring (TDM) databases containing data from HIV-infected 
patients.  
The primary objective of this study was to investigate the effect of tenofovir DF on the plasma 
nevirapine levels in HIV-infected patients. The secondary objective was to explore the effect of 
nevirapine on tenofovir plasma levels. In addition, the effect of tenofovir DF on efavirenz 
pharmacokinetics (and vice versa) was assessed to validate this TDM database analysis 
approach and to confirm results obtained from a healthy volunteer pharmacokinetic study5. 
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METHODS 
 
Study design  
This was a retrospective study that consisted of 6 groups of HIV-infected patients. Three 
control groups (1, 2, and 3) and 3 tenofovir DF groups (4, 5, and 6) were composed for 
comparing nevirapine and efavirenz data. The patients in the control groups were using 
nevirapine 200 mg twice daily (group 1), nevirapine 400 mg once daily (group 2) or efavirenz 
600 mg once daily (group 3), each without tenofovir DF. These were compared with groups 
using tenofovir DF 300 mg once daily combined with nevirapine 200 mg twice daily (group 4), 
nevirapine 400 mg once daily (group 5), or efavirenz 600 mg once daily (group 6). 
Furthermore, the tenofovir data from group 4 and group 5 were compared with the tenofovir 
data of group 6. 
This study included data that were collected from TDM samples during 2002 for the control 
groups 1-3 (ie, during a period when tenofovir DF was not yet available in the Netherlands) 
and during 2003 and 2004 for the tenofovir DF groups. Data were collected from the 
application form that accompanied each TDM sample, including: gender, age, body weight, 
indication for TDM, concomitant medication, plasma levels of efavirenz, nevirapine or 
tenofovir, and time after dosing of each medication. Medication adherence data were collected 
by interviewing the patients. Noncompliant patients were excluded from the analysis. In 
instances in which there was no information on use of other antiretrovirals or if the reason for 
TDM was suspected noncompliance, these data were excluded. Also, if there was 
concomitant use of rifampin or lopinavir/ritonavir or atazanavir (with or without ritonavir), these 
data were excluded from the study owing to the potential confounding effects on 
pharmacokinetics of nonnucleoside reverse transcriptase inhibitors or tenofovir. Furthermore, 
only the first nevirapine, efavirenz, and tenofovir plasma level of each patient was used (to 
exclude bias from repeated applications), and any patient included in one of the tenofovir 
groups was not allowed to contribute data for the control group. Each patient took the 
medication for at least 2 weeks, to ensure steady-state. For the analysis of nevirapine or 
efavirenz plasma levels, samples of all time points were used. 
For the analysis of tenofovir plasma levels, only samples at least 4 hours after medication 
intake were used in this study to avoid problems of interpretation during the absorption phase. 
Two approaches were used to compare the tenofovir plasma levels of the nevirapine groups 
(groups 4 and 5) with the efavirenz control group (group 6). First, tenofovir plasma levels 
(expressed as mg/L) of group 4 and 5 were compared with the plasma levels of group 6. 
Second, tenofovir concentration ratios of group 4 and 5 were compared with the concentration 
ratios of group 6. The concentration ratio represents the measured plasma concentration 
compared with the time-adjusted average concentration, as measured in a reference 
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population6. A population curve was constructed for the period 0-24 h after dose, using results 
of a study with tenofovir DF in 24 healthy volunteers7. These volunteers were given tenofovir 
DF 300 mg once daily over a 10-day period without any other medication. The curve was 
composed using the median values of the plasma concentrations for each time point.  
The HIV Monitoring Foundation (SHM) follows all HIV-infected patients as a national cohort, 
and patients have given informed consent. This cohort protocol has been approved by all 
institutional review boards of the 22 Dutch treatment centers for HIV-infected patients. 
 
Bio-analysis 
Nevirapine 
Nevirapine plasma concentrations were determined using a validated high-performance liquid 
chromatography assay with an ultraviolet detector according to a modified method8. An 
Omnispher 5 C18, 250x4.6 mm analytical column was used protected by a Chromguard RP ss 
10x3 mm column (both from Varian, The Netherlands). The method involved extraction of the 
drug from 150 µL human plasma by adding 150 µL perchloric acid (0.55 M). Fifty µL of the 
clear supernatant was injected onto the column. The flow rate was 1.5 mL/min. The mobile 
phase consisted of a mixture of phosphate buffer (600 mM; pH 6.5)/acetonitrile (75:4; vol/vol) 
that resolved the drug from endogenous matrix components and other drugs that were 
possibly present. Chromatographic analysis was performed at ambient temperature under 
isocratic conditions with a wavelength of 280 nm. The retention time of nevirapine was 5.6 
minutes. The concentrations of the quality controls used were 0.2, 1, and 5 mg/L. The intra- 
and interassay coefficients of variation were less than 4% for all quality controls. The lower 
limit of quantification was 0.15 mg/L. The rate of recovery of nevirapine from human plasma 
was 102%. 
 
Efavirenz 
Efavirenz plasma concentrations were determined according to a modified method9. After 
protein precipitation with acetonitrile, 20 µL of clear supernatant was injected into the 
chromatographic system. Chromatographic analysis was performed at ambient temperature 
with ultraviolet detection at 251 nm by using an Omnispher 5 C18, 150x4.6 mm analytical 
column (Varian, the Netherlands) protected by a Chromguard RP ss 10x3 mm column (Varian, 
The Netherlands). The flow rate was 1.0 mL/min. The mobile phase consisted of a mixture of 
potassium dihydrogen phosphate with acetonitrile (35%/65%; vol/vol)). The retention time of 
efavirenz was 4.7 minutes. The concentrations of the quality controls used were 0.4, 1.6, and 
10 mg/L. The intra- and interassay coefficients of variation were less than 1% for all quality 
controls. The lower limit of quantification was 0.20 mg/L. The rate of recovery of efavirenz from 
human plasma was 106%. Both the nevirapine and efavirenz assays were externally validated 
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by the International Program for Quality Control of Therapeutic Drug Monitoring in HIV 
Therapy10;11 and by the Quality Assurance Program for Clinical Measurement of 
Antiretrovirals12. 
 
Tenofovir 
Tenofovir plasma concentrations were determined by use of a high-performance liquid 
chromatography assay previously described7. A Symmetry Shield RP18 analytical column was 
used (3,5 µm; 150 by 4.6 mm; Waters, Etten-Leur, the Netherlands). The method involved 
extraction of the drug and internal standard, adefovir (Gilead Sciences, Foster City, CA), from 
100 µL human plasma by acetonitrile. After evaporation of the supernatant, 200 µL of 0.34% 
chloroacetaldehyde in 50 mM acetate buffer (pH 4.5) was added. Ten µL of the fluorescent 
compounds were injected onto the column. The flow rate was 1 mL/min. The mobile phase 
consisted of a mixture of phosphate buffer (50 mM, pH 6.8)/acetonitrile (96:4; vol/vol) that 
resolved the drug and the internal standard from endogenous matrix components and other 
drugs that were possibly present. Chromatographic analysis was performed at 30°C under 
isocratic conditions with extinction and emission wavelengths of 232 and 420 nm, respectively. 
The retention times of tenofovir and the internal standard, adefovir, were 6.34 and 3.90 
minutes, respectively. The concentrations of the quality controls used were 0.03, 0.21, and 
1.05 mg/L. The intra- and interassay coefficients of variation were less than 4% for all quality 
controls. The lower limit of quantification was 0.0045 mg/L. The rate of recovery of tenofovir 
from human plasma was 86%. The tenofovir assay was externally validated by the Quality 
Assurance Program for Clinical Measurement of Antiretrovirals12. 
 
Statistical analysis 
All statistical evaluations were performed with SPSS software version 11.0 (SPSS Inc. 
Chicago, IL, USA). Plasma levels of nevirapine, efavirenz, tenofovir, and tenofovir 
concentration ratios were log transformed before statistical analysis. Geometric means were 
calculated for the different groups; the control groups of nevirapine and efavirenz were 
compared with their accessory groups with use of the 2-sided Student t-test for independent 
samples. The tenofovir plasma levels and tenofovir concentration ratios of group 4, 5, and 6 
were compared using an one-way analysis of variance (ANOVA). The values of weight, age, 
and time of sampling were not transformed and were compared using the Mann-Whitney test. 
A P-value <0.05 was considered significant in all analyses. 
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RESULTS 
 
Demographics  
The median (range) demographic data for each group are reported in Tables 1A and 1B. Data 
were collected for 272 patients in the 200 mg twice daily nevirapine control group (group 1) 
and for 39 in the tenofovir DF + nevirapine twice daily group (group 4). In both the control and 
tenofovir DF groups, approximately 75% of patients were male. The 400 mg once daily 
nevirapine control group (group 2) was composed of 18 patients, whereas the tenofovir DF + 
nevirapine once daily group (group 5) included 94 patients. The distribution of males and 
females in these two groups was comparable to that of the other groups, including 
approximately 75% male subjects. 
For efavirenz, data were collected for 126 patients in the efavirenz control group (group 3) and 
for 118 in the tenofovir DF + efavirenz group (group 6). In the control and tenofovir DF groups 
81% and 73% of patients were male, respectively.  
In the efavirenz + tenofovir DF control group (group 6) 70 patients were included, whereas in 
the nevirapine once daily + tenofovir DF group (group 5) and in the nevirapine twice daily + 
tenofovir DF group (group 4) 63 and 17 patients were included, respectively. The groups used 
for the tenofovir plasma levels and tenofovir concentration ratios (group 4, 5, and 6) were 
smaller than their accessory groups 1, 2, and 3, because for group 4, 5, and 6, only samples 
were used at least 4 hours after medication intake (Table 2). No significant differences were 
found between the nevirapine control groups and the tenofovir DF groups for age. For weight 
there was a significant difference between the patients in the 200 mg nevirapine control group 
(group 1) and the nevirapine 200 mg twice daily + tenofovir DF 300 mg once daily group 
(group 4); the weights were 76.7 kg and 69.5 kg for group 1 and 4, respectively. 
 
Pharmacokinetic data 
No significant differences were found between the nevirapine control groups and the tenofovir 
DF groups for time after intake of medication and nevirapine concentrations (Table 2). 
For the efavirenz groups (3 and 6) a significant difference was observed between the groups 
with and without tenofovir DF in time after intake (Table 2), but not in efavirenz plasma levels. 
Finally, no difference was found between the control group (6) and the nevirapine + tenofovir 
DF groups (4 and 5) regarding tenofovir plasma levels and tenofovir concentration ratios 
(Table 2). Only time after intake of the 200 mg nevirapine tenofovir DF group (group 4) 
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Table 1B: Demographic Data for Tenofovir DF groups  
 TDF group (4) 
200 mg NVP BID + 
300 mg TDF 
TDF group (5) 
400 mg NVP QD  
+ 300 TDF 
TDF control group (6)  
Efavirenz 600 mg QD 
+ TDF 300 mg QD 
N(%) M 
          F 
12 (63) 
7 (37) 
45 (71) 
18 (29) 
53 (76) 
17 (24) 
Age (y) 39.0 (19-54) 40.0 (21-61) 41.5 (25-68) 
Weight (kg) 70 (39-97) 72 (38-115) 75 (52-106) 
M=males, F=females 
Data are medians (range) NVP=nevirapine, EFV=efavirenz, TDF=tenofovir disoproxil fumarate 
 
differed significantly from the control group 6, but this is corrected for by using concentration 
ratios. 
All the separate plasma levels from the different groups (nevirapine, efavirenz, and tenofovir) 
are shown in Figures 1, 2, and 3, respectively. The tenofovir concentration ratios of the 3 
tenofovir groups are presented in Figure 4. 
 
 
DISCUSSION 
 
The primary objective of this study was to investigate the effect of tenofovir DF (300 mg once 
daily) on the plasma nevirapine (200 mg twice daily or 400 mg once daily) levels. This 
retrospective study demonstrated that coadministration of tenofovir DF with nevirapine (200 
mg twice daily or 400 mg once daily) in a large number of HIV-infected patients had no effect 
on nevirapine plasma levels compared with administration of nevirapine alone. 
The secondary objective of this study was to explore the effect of nevirapine on tenofovir 
plasma levels. This was studied by comparing tenofovir plasma levels and tenofovir 
concentration ratios from patients using nevirapine (200 mg twice daily or 400 mg once daily) 
and tenofovir DF (300 mg once daily) with the levels in patients using efavirenz (600 mg once 
daily) and tenofovir DF. The results of this study showed that nevirapine, whether 
administered once or twice daily, had no significant effect on the tenofovir plasma levels or 
concentration ratios.  
Furthermore, the effect of tenofovir DF on efavirenz pharmacokinetics (and vice versa) was 
assessed and no effects were found. 
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Figure 1A: Nevirapine twice daily plasma levels
Figure 1B: Nevirapine once daily plasma levels 
Figure 2: Efavirenz plasma levels 
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The efavirenz data from the efavirenz groups are consistent with the results from a crossover 
drug-drug interaction study conducted in healthy volunteers5. As such, results from this study 
demonstrated the potential usefulness of using a TDM database to assess possible drug-drug 
interactions in HIV-infected patients. 
The sometimes large differences in sample size in the different study groups are the result of 
the retrospective nature of this study, and inherent to TDM database analyses. 
Although crossover drug-drug interaction studies allow for the most precise assessment of 
pharmacokinetics and detection of small, clinically insignificant drug-drug interactions, 
appropriate use of clinical data, including TDM results, offer an additional useful tool for 
assessing drug-drug interactions. This is of particular importance when pharmacokinetic 
studies in healthy volunteers may not be appropriate, eg, for a drug like nevirapine in which an 
Figure 3: Tenofovir plasma levels
Figure 4: Tenofovir concentration ratios
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increased risk of serious liver toxicity in subjects with higher CD4 cell counts has been 
observed13. 
In this study plasma concentrations of tenofovir were determined during its elimination phase, 
at least 4 hours after intake. In routine clinical care it is often difficult to draw a blood sample at 
a strictly defined timepoint and because the data of this study were collected from routine TDM 
samples, the samples were drawn at different times after intake; therefore, tenofovir 
concentration ratios were used for comparison across groups to correct for time after intake. 
Additionally, for nevirapine all time points during dosing intervals were used because time after 
intake is not relevant owing to the long half-life of this agent14. For efavirenz it is known that 
the half-life of efavirenz is 40-55 hour, and therefore, we decided to use samples of all 
timepoints during the dose interval15.  
Because tenofovir is a prodrug that requires intracellular activation to an active diphosphate 
derivate, and a relationship between the plasma tenofovir levels and intracellular derivate has 
not been established yet, measuring the intracellular tenofovir diphosphate levels might be 
more useful than measuring plasma levels. However, measurement of intracellular levels of 
tenofovir diphosphate is technically difficult, time consuming and not widely available. For that 
reason measuring plasma levels of tenofovir is the alternative. 
Furthermore, no data were available for patients who were using only tenofovir DF, therefore 
plasma concentrations of tenofovir and tenofovir concentration ratios from patients to whom 
nevirapine was coadministered were compared with plasma concentrations of tenofovir and 
tenofovir concentration ratios in the efavirenz group.  
The mean tenofovir concentration ratios of the 3 tenofovir DF groups 4, 5, and 6 were 0.57, 
0.53, and 0.59, respectively (Table 2) compared with the reference population7. These results 
suggest that tenofovir concentrations in this study are lower than the tenofovir concentrations 
in the reference population. The pharmacokinetics of tenofovir has been evaluated in healthy 
volunteers and HIV-infected individuals. Tenofovir pharmacokinetics have been found to be 
similar between these populations2. 
However, several reasons can explain the difference between the tenofovir results from this 
study and the reference population. First, a high fat meal (700-1000 kcal) can have an effect, 
as coadministration with food increases the absorption2. The volunteers in the reference 
population took their tenofovir DF with a standardized breakfast of 550 kcal7, whereas for the 
HIV-infected patients of this study, this information is not known, because tenofovir DF may be 
taken with or without food2. Second, the medication intake of the healthy volunteers was 
monitored and the time was recorded carefully, as was the time of blood drawing. The patients 
in this study took their medications at home and the time was recorded during their visit at the 
hospital and therefore probably subjected to more variation. 
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Although a small but significant difference was found between the body weights of the 200 mg 
nevirapine control group and the tenofovir DF group, it is unlikely that this finding has 
influenced the results as body weight is not associated with plasma nevirapine 
concentrations16. 
 
In conclusion, the data from this study demonstrate that the addition of tenofovir DF to 
efavirenz or nevirapine in HIV-infected patients does not influence the plasma levels of 
nevirapine or efavirenz. Furthermore, neither efavirenz nor nevirapine have any effect on the 
plasma levels of tenofovir. This suggests that these drugs can be coadministered without the 
need for dose adjustments. 
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ABSTRACT 
 
Background: Single-dose nevirapine is a highly cost-effective strategy to reduce perinatal 
HIV-1 transmission. Its major disadvantage is the selection of nevirapine resistance in 20% 
to 30% of women, probably attributable to the long elimination half-life of nevirapine. To 
develop intervention strategies, it is important to know the interpatient variability in nevirapine 
half-life in women receiving a single dose of nevirapine 
Methods: HIV-negative, healthy, nonpregnant Dutch women were eligible for this study. 
After administration of a single 200 mg dose of nevirapine to the subjects, blood was 
sampled for measurement of nevirapine twice a week for a total of 21 days. Nevirapine 
plasma levels were determined by a validated high-performance liquid chromatography 
method with a lower limit of quantification of 0.15 mg/L. The primary endpoint was the first 
sample with an undetectable nevirapine concentration. 
Results: Forty-four subjects participated. The median age, height and body weight 
(interquartile range) were 26 (21-33) years, 1.72 (1.68-1.75) m, and 64 (59-75) kg, 
respectively. The median elimination half-life of nevirapine was 56.7 hours with a range of 
25.6 to 164 hours. The time to the first undetectable nevirapine plasma concentration was 10 
days in 4 subjects, 14 days in 12 subjects, 17 days in 12 subjects, and 21 days in 9 subjects. 
In the remaining 7 subjects, nevirapine was still detectable on day 21, the last day of 
sampling. Time to an undetectable nevirapine plasma concentration was influenced by oral 
contraceptive use but not by age, height, body weight, body surface area, alcohol use, or 
smoking.  
Conclusions: Most women who received a single 200 mg nevirapine dose still had 
detectable plasma concentrations of nevirapine after more than 2 weeks. This information is 
valuable for designing intervention studies to prevent the development of nevirapine 
resistance. 
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INTRODUCTION 
 
Without the use of preventive measures, the risk of mother-to-child transmission (MTCT) of 
HIV-1 is estimated to vary between 25% and 48%. Several preventive strategies have been 
evaluated, but most of them are too expensive to implement in resource-limited countries. 
The regimen of a single dose of nevirapine to the mother just before delivery and a single 
dose of nevirapine to the newborn between 24 to 72 hours after birth reduces the risk of 
MTCT by 50% and is affordable in many situations1. 
Recent studies, however, have shown that this single dose to the mother can induce 
nevirapine resistance in 20% to 30% of the mothers2. The development of this resistance 
may have major implications. First, it is uncertain whether a subsequent course of nevirapine 
is still effective for the prevention of MTCT when these women become pregnant again. 
Second, the efficacy of subsequent treatment with nevirapine-based highly active 
antiretroviral therapy (HAART) regimen will be diminished when the patient is harboring a 
resistant virus3. Finally, nevirapine-resistant strains may be transmitted to other people. 
The mechanism of the occurrence of nevirapine resistance after a single dose is most likely 
related to the long elimination half-life of nevirapine and the low genetic barrier to resistance. 
Small pharmacokinetic studies have demonstrated that the elimination half-life after a single 
dose of nevirapine is approximately 60 hours4. This implies that plasma concentrations of 
nevirapine are detectable in mothers for several days after delivery. The subtherapeutic but 
detectable plasma levels present the perfect environment for the occurrence of resistance, 
as the concentrations may be subinhibitory for several days.  
The primary objective of this study was to investigate the intersubject variability in and 
potential influencing factors of the decay of plasma nevirapine concentrations after a single 
200 mg dose. A secondary objective was the evaluation of the use of saliva as an alternative 
to blood sampling for measurement of nevirapine concentrations. The study was conducted 
in the Netherlands as a prelude to a similar one in Tanzania. 
 
 
METHODS 
 
The present study was a single-centre, open-label, single-dose, single-period 
pharmacokinetic study. Nonpregnant healthy women aged 18 to 40 years were eligible for 
enrollment after pre-entry and laboratory evaluation. Women who tested positive for HIV 
and/or hepatitis B or C virus were excluded. The study protocol was reviewed and approved 
by Ethics Committee of the Radboud University Medical Centre Nijmegen, The Netherlands. 
Informed consent was obtained from all women prior to enrollment. 
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All study subjects received a single oral dose of 200 mg of nevirapine on day 0, and the 
Principal Investigator directly observed medication ingestion. Sampling of blood and saliva 
was done just before and 3, 7, 10, 14, 17, and 21 days after a single 200 mg dose of 
nevirapine. Stimulated saliva was obtained by a salivette (Sarstedt, Etten-Leur, the 
Netherlands) using a dental cotton roll impregnated with citric acid (20 mg), which stimulates 
the salivary flow. Study subjects were asked to chew on the cotton roll for approximately 1 
minute. Saliva was obtained by centrifugation of the cotton roll. The plasma and saliva 
samples were stored at – 40°C until analysis. Plasma and saliva concentrations of nevirapine 
were determined by a validated high-performance liquid chromatography assay with 
ultraviolet detection5. The lower and upper limits of quantification were 0.15 and 15 mg/L, 
respectively. The intra- and interday precision ranged from 1.3% to 3.9% and from 1.9% to 
3.0%, respectively. The accuracy of the assay ranged from 91.5% to 102.6%. 
The typical median inhibitory concentration (IC50) value of nevirapine is 0.1 mg/L; corrected 
for 60% protein binding, this corresponds to a plasma level of approximately 0.2 mg/L. It is 
currently unknown, however, at what plasma level nevirapine selects for resistance. Clinical 
studies have determined that effective concentrations of nevirapine are greater than 3 to 4 
mg/L, while levels less than 0.1 to 0.2 mg/L do not have selective pressure. Therefore, any 
plasma level between 0.2 and 3.0 mg/L has been defined by us as subtherapeutic. The 
following patient factors were tested for an association with the time to undetectable 
nevirapine plasma concentration: age, height, weight, body surface area, alcohol use, 
smoking habits, and oral contraceptive use. 
 
 
RESULTS 
 
Forty-four non-pregnant healthy women were enrolled in the protocol. The median age, 
height, and body weight (interquartile range) were 26 (21-33) years, 1.72 (1.68-1.75) m, and 
64 (59-75) kg, respectively. Other than 1 Asian woman and 1 woman of mixed background, 
the remaining 42 women were Caucasian.  
The pharmacokinetic parameters of the study subjects are presented in Table 1. The median 
elimination half-life (t1/2 ) for nevirapine in plasma was 56.7 hours with a range of 25.6 to 164 
hours. Maximum nevirapine plasma levels at day 3 (first post-dose measurement) ranged 
from 0.36 to 1.59 mg/L with a median value of 0.71 mg/L. The median time to the first 
undetectable nevirapine plasma concentration was 17 days. There were 7 subjects in whom 
nevirapine was still detectable on day 21, the last day of sampling (Fig. 1). 
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Except for oral contraceptive use, none of the other patient characteristics seemed to be 
related to the time to an undetectable nevirapine concentration in plasma. There were 17 
women who reported taking oral contraceptives, and they had a median time to the first  
 
 
Table 1: Pharmacokinetic parameters of nevirapine after a 200 mg single oral dose (median 
values + range) 
 Plasma Saliva 
CL/F (L/h.kg) 
T-half (h) 
Vd/F (L/kg) 
Cmax (mg/L) 
Time to undetectable 
concentration (days) 
0.04 (0.02 – 0.10) 
56.7 (25.6 - 164.1) 
2.8 (0.8 - 5.3) 
0.71 (0.36 - 1.59) 
17 (10 - >21) 
 
77.1 (35.8-264.7) 
 
0.35 (0.03-0.77) 
14 (7-21) 
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Figure 1: Distribution of time to undetectable NVP concentration (in days) for the 44 included 
subjects 
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undetectable nevirapine plasma level of 21 days. This was significantly longer than for the 
remaining 27 women who reported not taking oral contraceptives (14 days; P < 0.001). The 
difference in median plasma half-life of nevirapine in oral contraceptive users versus 
nonusers was not significant (69.7 versus. 52.8 hours), respectively (p=0.053). 
Saliva nevirapine concentrations were approximately half of the values observed in plasma. 
Nevirapine levels in saliva were significantly correlated with nevirapine levels in plasma at 
the first day of sampling: [NVP]saliva = -0.002 + 0.495 x [NVP]plasma (R2=0.531, F = 47.496, p < 
0.001). Time to an undetectable nevirapine concentration was shorter in saliva than in 
plasma: median values were 14 and 17 days, respectively (Fig. 1).  
 
 
DISCUSSION 
 
In this study of 44 healthy, non-pregnant, HIV-1-uninfected Dutch women, a single dose of 
200 mg of nevirapine had an average half-life of 56.7 hours (or 52.8 hours women who did 
not use contraceptives). Nevirapine levels remained detectable in plasma for a median of 17 
days (range: 10 to >21 days). In 16% of women, nevirapine was detectable at the last 
measured time point, 21 days after the single dose. Thus, a single dose of nevirapine was 
associated with persistent measurable drug levels beyond 3 weeks after administration. 
It is clear that our study population of healthy non-pregnant Dutch women of childbearing age 
is not similar to the setting in Tanzania (or other sub-Saharan African countries), where HIV-
infected pregnant women are black and have different dietary habits, body weights, and co-
medication, for example. Nevertheless, the median nevirapine half-life that we observed in 
our group of 44 subjects (56.7 hours) is not very different from the average value as reported 
by Musoke et al4 in a smaller group of pregnant HIV-infected Ugandan women receiving 
single-dose nevirapine (61.3 hours). We were not able to identify any significant patient 
factor (other than oral contraceptive use) that was associated with an influence on nevirapine 
half-life. Oral contraceptives may be able to inhibit hepatic metabolism of nevirapine, 
although this effect was previously not observed (and thus not expected by us) in a formal 
drug-drug interaction study6. It must be noted, however, that our study was not designed to 
address causality between oral contraceptive use and nevirapine half-life. 
Most importantly, our data describe the window of opportunity for the virus to select for 
nevirapine resistant mutations. The longer the time to an undetectable nevirapine level in 
plasma, the longer the virus has time to replicate. In 2000, Jackson et al7 reported that 
among the 15 women in the HIVNET 006 trial in whom virus was tested for the K103N 
mutation, the 3 women who developed the mutation had a significantly longer elimination 
half-life of nevirapine than the 12 women in whom no resistance was detected (74.8 versus 
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51.8hours; p=0.01). Thus, one of the most rational interventions is the addition of other 
antiretroviral agents after delivery to cover this window of opportunity for the virus to select 
for nevirapine resistance. Recently, preliminary data were presented that short courses (4-7 
days) of zidovudine+lamivudine (Combivir®) added to single-dose nevirapine in the 
prevention of MTCT significantly reduced the development of nevirapine resistance when 
compared to no intervention8. One could speculate that this will not be sufficient to prevent 
the development of all nevirapine mutations. Indeed, nevirapine resistance was not fully 
absent in the intervention arms. Extending the duration of administering additional 
antiretroviral agents after delivery may also increase the development of resistance to these 
drugs.  
 
It may be attractive to use alternative methods, other than collecting blood samples for 
measurement of exposure to nevirapine. As reported earlier, nevirapine can be detected in 
saliva9. In our study, we observed a very strong correlation between nevirapine levels in 
saliva versus plasma, and in almost al subjects an undetectable nevirapine level was 
detected 3 days earlier in saliva than in plasma (see Fig. 1). Collecting saliva samples for 
measurement of nevirapine levels has the advantage of taking samples at home (by the 
patient herself; with no skilled personnel needed), less discomfort for the patient, and less 
infection risk for health care workers who draw the sample.  
In conclusion, most women who received a single nevirapine dose of 200 mg still had 
detectable plasma concentrations of nevirapine after more than 2 weeks. This information is 
valuable for designing intervention studies to prevent the development of nevirapine 
resistance. 
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INTRODUCTION 
 
This thesis intended to make a contribution to therapeutic drug monitoring (TDM) of HIV 
treatment and bridging the laboratory and clinic. TDM is employed to measure and follow 
blood drug levels so that the most effective dosage can be determined, for each individual 
patient, with toxicity prevented. TDM is also utilized to identify noncompliant patients. 
Many different factors influence blood drug levels such as analytical techniques, patient 
factors, and drug factors. For analytical techniques it is important to know the quality of the 
assay. The patient factors include age, weight and co-morbidity. Also patient compliance is a 
key factor. For drug factors, the route of administration of the drug, the drug's absorption, 
excretion, delivery rate, drug dosage, and co-medications should be taken into consideration 
during TDM. 
The studies described in this thesis have explored the following aspects of TDM: analysis of 
protease inhibitors in plasma and the stability of protease inhibitors in plasma, cross reaction 
of efavirenz on drug screening assay, quality of TDM services, drug-drug interactions, and 
drug levels of single-dose nevirapine. 
 
 
BIO-ANALYSIS OF ANTIRETROVIRAL DRUGS AND QUALITY OF TDM SERVICES 
 
Bio-analysis of antiretroviral drugs in plasma is a requirement for TDM. Since the introduction 
of the protease inhibitors in 1995, methods have been developed for the analysis of single 
protease inhibitors and for simultaneous determination of several protease inhibitors1. In 
chapter 1 a bio-analytical method for the simultaneous determination of 6 protease inhibitors 
and nevirapine is described. The lower limit of quantification for the several antiretroviral 
drugs is low enough for quantitation of concentrations below trough concentrations of the 
single protease inhibitors or below presumed therapeutic thresholds for protease inhibitors. 
This is in contrast with the results of three participants in the international interlaboratory 
quality control program described in chapter 4. These participants reported to have their 
lower limits of quantification above low or trough concentrations of amprenavir, indinavir, and 
ritonavir. This quality control program also showed that lower concentrations are more 
difficult to assess accurately than medium or higher plasma concentrations. Furthermore, the 
program revealed that about 20% of the results reported were outside the acceptable limits 
of 80% to 120% accuracy and only 3 out of 30 laboratories were able to report all results 
within the acceptable limits. 
As a result, the possible negative impact of the analysis on TDM and pharmacokinetic 
studies is probably larger than expected because dose adjustments and switching therapy 
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might occur based on inaccurate information about concentrations and pharmacokinetic 
studies might produce incorrect results. 
The validation of bio-analytical high-performance liquid chromatography (HPLC) methods 
has been described by the International Conference on Harmonization2. The intent of bio-
analytical HPLC methods validation is to demonstrate that the method is suitable for its 
intended purpose, accurate quantitative measurement of analytes in a given biological 
matrix, such as blood, plasma, serum or urine. According to the guidelines this validation 
includes determination of selectivity, accuracy, precision, recovery, stability, lower limit of 
quantification, and calibration/standard curve concentration-response. One important item is 
not included in the guidelines: participating in an external quality control program if available 
for the analyte tested. When an external quality control program is part of the validation of a 
new method, laboratories are alerted to undetected analytical errors and are able to improve 
their assays 
As described in chapter 4, an external quality control program is helpful to detect possible 
problems with the analytical method. The reasons for unsatisfactory measurements were 
reported. There was an explanation for 86% of all the unsatisfactory results. The majority of 
the reasons were of technical origin, varying from dilution error, acceptance of an analytical 
run even though controls were out of range, to aging stock solutions, and stock solutions 
made of impure substances. 
Papers reporting new analytical methods should include successful results of participating in 
a quality control program to assure acceptable accuracy of the reported method. For 
example the recently published methods for the determination of nucleoside analogue 
reverse transcriptase inhibitors3 and the determination of protease inhibitors4 by HPLC 
reported satisfactory results obtained from a quality control program and for that reason 
these methods are suitable for TDM as long as participation in a quality control program is 
continued successfully. Furthermore, clinicians should make sure that the laboratory, to 
which their TDM samples are sent, participates in an extern quality control program at least 
twice a year successfully. In addition, papers that describe results from pharmacokinetic 
studies and trials in which antiretrovirals are determined in various centers, should also 
include results from external quality control programs, to assure the reliability of the results. 
Recently, several papers are published containing this information5-8. This is important 
because the results of these kinds of studies can have great impact on the treatment of HIV-
infected patients. The importance of an accurate method for quantification of antiretroviral 
drugs should not be underestimated.  
In addition when using another matrix than the one the assay is developed for, a (partly) 
revalidation is needed. The recovery from the matrix, the stability, the intraday and interday 
variation and interfering substances might be different. Most HPLC methods described are 
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developed for measurements in plasma. There is no quality control program available for the 
measurement of any drug in saliva, or seminal plasma. Nevertheless, when reporting data of 
drugs in other matrices than plasma, validation results should be added. Published data of 
indinavir in cerebrospinal fluid (CSF) and in seminal plasma9, zidovudine and lamivudine in 
seminal plasma10, lopinavir and indinavir in CSF and seminal plasma11 only contain a 
reference of an HPLC method in blood plasma. On the other hand Solas et al12 measured 
protease inhibitors in seminal plasma and CSF and reported how they performed the 
analysis together with the validation parameters. This should be required before a paper can 
be accepted by a scientific journal. 
In chapter 6 data of lopinavir in seminal plasma are presented without a complete set of 
validation data of the analysis. Only the intra- and interday variations are presented, although 
a validation needed for another matrix was performed. In fact these data should have been 
added to the article in chapter 6. 
Furthermore, long-term stability of the antiretroviral agents in plasma has to be known, 
especially for retrospective pharmacokinetic studies. As described in chapter 2 almost all 
protease inhibitors currently available are stable for at least 18 months at –20oC. Before a 
pharmacokinetic retrospective study is conducted, stability of the drug studied should be 
determined. According to the guidelines for bio-analytical method validation2, long-term 
stability should be tested by evaluating at least three aliquots of each low and high control 
samples after a storage time that exceed the time between the date of first sample collection 
and the date of last sample analysis. These control samples usually contain an organic 
solvent in which the drug is dissolved. Patient samples on the other hand do not contain 
organic solvents, but contain possible metabolites and comedication. To be really sure of the 
stability, it might be better to use plasma samples of HIV-infected patients to assess the long-
term stability, instead of artificial quality control samples. Anyhow, stability should be tested 
for a long period. During validation of a new developed method, long-term stability is usually 
tested for 2 to 6 months at the most (chapter 2), while for example the 2NN study13 collected 
efavirenz and nevirapine samples during 2 years (2000 and 2001) and analyzed them in 
2004 (personal communication, B. Kappelhoff) without any comment on the stability of these 
agents. The results of this study might be influenced by the possible degradation of efavirenz 
or nevirapine. Therefore, results of retrospective pharmacokinetic studies should always be 
accompanied by stability tests for at least the duration of storage, preferably in HIV-infected 
patient plasma samples.  
 
Besides the quality of the analyses, the interpretation of the plasma levels as part of TDM is 
of importance. The results of the patient cases that were part of the interlaboratory quality 
control program revealed to be variable among the respondents and the recommendations 
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given were partly incomparable (chapter 5). The drug levels were easy to judge, as ± 90% 
were able to correctly do so. Therapeutic ranges of the protease inhibitors and 
nonnucleoside reverse transcriptase inhibitors in plasma are commonly known and published 
before14;15.  
On the other hand chapter 5 showed a large variability among the respondents in their ability 
to give satisfactory recommendations concerning dose adjustments, changes to the regimen 
and drug-drug interactions. The variation in recommendations may result in implications for 
the patient.  
 
 
PHARMACOKINETICS 
 
Pharmacokinetics is the study of the time course of a drug in the body after administration. 
After dosing, absorption, distribution, metabolism, and excretion of the drugs in the body will 
occur. Biological, physiological, and physicochemical factors may influence the transfer 
processes of drugs. Because of comorbidity (tuberculosis (TB), hepatitis etc.) HIV-infected 
patients may need other drugs that might interact with the antiretroviral drugs. 
HIV-infected patients usually receive a wide variety of drugs in addition to the antiretroviral 
drug regimen. Every year new data on antiretroviral drug interactions are published or 
presented in scientific meetings and there are numerous review articles16-19 and websites 
listing all possible drug-drug interactions with antiretroviral agents.  
Sheehan et al20 have evaluated several antiretroviral drug interaction sites for quality, 
comprehensiveness, and functionality, and are planning to conduct this review on a regular 
basis. However, the management of HIV is growing in complexity as new antiretroviral 
agents are developed with accompanying possible drug-drug interactions. So complete data 
will hardly be available in such review articles.  
In chapter 7 tenofovir DF is studied in combination with the first-line tuberculostatic agent 
rifampin in healthy subjects. About one third of all the people infected with HIV are also 
infected with Mycobacterium tuberculosis (TB). The majority of persons co-infected with HIV 
and TB reside in poor countries with most cases occurring in sub-Saharan Africa and South 
and South-East Asia21-23. Although highly effective therapy exists for both HIV and TB, 
concomitant administration is fraught with difficulties. Problems arise when giving these two 
therapies concomitantly and sometimes HIV therapy is delayed to minimize the risk of drug-
drug interactions and toxic effects. It is known that patients with low CD4 cell count need 
HIV-therapy as well as TB-therapy. To enlarge the choice of antiretroviral agents that can be 
combined with rifampin without risks, the combination of tenofovir DF and rifampin was 
studied. 
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Coadministration of tenofovir DF and rifampin did not result in changes in the values of the 
tenofovir pharmacokinetic parameters and the values of the rifampin pharmacokinetic 
parameters were comparable to those found in the literature. Therefore, tenofovir DF and 
rifampin can be coadministered without dose modifications of either one of the drugs. 
 
Although no interaction between tenofovir DF and both efavirenz and nevirapine was 
expected, it could not be excluded. Tenofovir has been found to increase plasma exposure of 
didanosine and decreases atazanavir plasma levels both unexpectedly24. Furthermore, all 
other currently available anti-HIV agents were tested already in combination with tenofovir 
DF24 except for nevirapine. For the completeness tenofovir DF combined with nevirapine had 
to be studied. In chapter 8 a study is described in which tenofovir DF was studied in HIV-
infected patients when combined with nevirapine and efavirenz versus efavirenz or 
nevirapine alone. This study demonstrated that coadministration of tenofovir DF with 
nevirapine or efavirenz in a large number of HIV-infected patients had no effect on nevirapine 
or efavirenz plasma levels compared to administration of nevirapine alone. 
In contrast with the study in chapter 7 where tenofovir DF was studied in healthy subjects, 
the study in chapter 8 was conducted in a TDM database of HIV-infected subjects. Both 
approaches have their advantages. A study with HIV-infected patients will have the 
disadvantage of a heterogeneous group, high variation and possible toxicity. On the other 
hand, HIV-infected patients are the target group for whom the drugs are meant and HIV-
infected patients may have another metabolism25 than healthy subjects have. On the 
contrary, a study with healthy subjects warrants a homogeneous group, the correct number 
of subjects based on statistical calculations to be able to draw conclusions, sampling time 
after drug intake is the same for the complete group of subjects, and complete 
pharmacokinetic curves can be obtained. 
Nevertheless, for studying the possible interaction between tenofovir DF and nevirapine in 
chapter 8, HIV-infected patients in a TDM database were chosen because giving nevirapine 
to healthy volunteers might be a problem. Subjects with higher CD4 cell counts have an 
increased risk of serious liver toxicity26. This database study with HIV-infected patients 
proves that this approach is also a useful mechanism.  
 
In recent years, the use of nevirapine has attracted considerable attention because of its 
efficacy in clinical trials in reducing mother to child transmission (MTCT). 
The first trial in which nevirapine was used for prevention of MTCT was the HIVNET012 trial 
in 199927. Since then various studies with nevirapine have been performed demonstrating 
that nevirapine is a simple inexpensive prophylaxis, which can dramatically reduce the risk of 
MTCT. However, recent studies have shown development of nevirapine resistance28.  
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In Chapter 9 a study is described in which a single-dose nevirapine is given to healthy female 
subjects. The time to an undetectable nevirapine plasma level varied between 10 and more 
than 21 days. Another study in HIV-infected Thai women5 was performed, which confirmed 
our data. They also found significant nevirapine concentrations for up to 20 days.  
The concentration to give 50% inhibition (IC50) for nevirapine is approximately 10 ng/mL, 
which is approximately 400-500 times lower than the plasma concentration achieved with 
200 mg twice daily nevirapine. In treatment of HIV-infected patients, 200 mg of nevirapine 
twice daily is the recommended dose; this dose was found to be the maximal effective dose 
with acceptable toxicity29. The steady-state concentrations achieved with this dosing regimen 
are 4.5 ± 1.9 mg/L29. 
However, the women who are given single dose nevirapine to reduce the risk of MTCT do 
not reach steady-state nevirapine levels. The plasma concentration needed to prevent HIV-
transmission and to develop resistance is not known. 
Furthermore, during the HIVNET012 trial with single dose nevirapine, only 200 mg nevirapine 
was tested. This was probably the most practical choice, as nevirapine tablets contain 200 
mg nevirapine.  
The lack of data (plasma concentration needed to prevent MTCT and lowest plasma at which 
resistance development may occur) raises the question why a lower single dose of 
nevirapine was never tested. A lower dose will lead to undetectable plasma nevirapine levels 
more rapidly than single dose 200 mg nevirapine will, and might lead to less resistance 
development, while it might be as effective as single dose 200 mg nevirapine is. 
Nevertheless, while work must continue to identify more efficacious and safe regimens to 
prevent MTCT, preventing women from becoming HIV-infected should remain an important 
issue. 
 
 
FINAL THOUGHTS 
 
The studies in this thesis aimed to make a contribution to TDM of HIV treatment by bridging 
the laboratory with the clinic. 
Initially, the quality control program of antiretroviral drugs in plasma should be continued and 
all laboratories measuring antiretroviral drugs for TDM or pharmacokinetic studies should 
participate in this or a similar program on a regular basis. This way the quality of the analysis 
is guarded. Furthermore, new approved antiretroviral drugs, which are determined in plasma, 
should be included in the quality control program. The quality of the determination of the 
antiretroviral drugs is an important starting point for TDM. 
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Next, advises concerning treatment of HIV-infected patients are an important part of TDM 
also and should be given by well-trained personnel. As reported in chapter 5, levels of 
knowledge regarding HIV treatment appeared to be variable which could have consequences 
for the patients. Therefore, the quality control program should include patient cases on a 
regular basis so health care professionals in charge of treatment of HIV-patients can test 
their knowledge. 
In addition, new antiretroviral drugs should be tested for possible interactions with other 
antiretroviral drugs and other possible comedication because interactions although maybe 
not expected can never be excluded.  
 
Finally, to achieve maximum information and quality of care for the (HIV)-patients, TDM 
should be a close collaboration between laboratory and clinic.  
 
 
REFERENCES 
 1.  Aarnoutse RE, Verwey-van Wissen CPWGM, Underberg WJM, Kleinnijenhuis J, Hekster YA, 
Burger DM. High-performance liquid chromatography of HIV protease inhibitors in human 
biological matrices. Journal of Chromatography B Biomed Sci Appl 2001;764:363-84. 
 2.  Anonymous. Guidance for Industry Bioanalytical Method validation.  2001.  
 3.  Verweij-van Wissen CP, Aarnoutse RE, Burger DM. Simultaneous determination of the HIV 
nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, 
zidovudine and abacavir in human plasma by reversed phase high performance liquid 
chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005;816:121-29. 
 4.  Tribut O, Verdier MC, Arvieux C, Allain H, Michelet C, Bentue-Ferrer D. Simultaneous 
Quantitative Assay of Atazanavir and 6 Other HIV Protease Inhibitors by Isocratic Reversed-
Phase Liquid Chromatography in Human Plasma. Ther Drug Monit 2005;27:265-69. 
 5.  Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, Musoke P, Capparelli E, 
Mirochnick M. Persistence of nevirapine exposure during the postpartum period after 
intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of 
mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005;38:283-88. 
 6.  van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW. Absence of 
circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing 
regimen in HIV-1-infected patients. Br J Clin Pharmacol 2005;59:398-404. 
 7.  Molina JM, Peytavin G, Perusat S, Lascoux-Combes C, Sereni D, Rozenbaum W, Chene G. 
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the 
treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med 
2004;5:99-104. 
 8.  Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard 
B, Pozniak A. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when 
administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol 
2005;59:38-42. 
General discussion 
  139 
 9.  van Praag RME, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner-Foisy ML, 
Sommadossi JP, Burger DM, Lange JMA, Hoetelmans RMW, Profijt M. Enhanced penetration of 
indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 
2000;14:1187-95. 
 10.  Pereira AS, Kashuba AD, Fiscus SA, Hall JE, Tidwell RR, Troiani L, Dunn JA, Eron JJ, Jr., 
Cohen MS. Nucleoside analogues achieve high concentrations in seminal plasma: relationship 
between drug concentration and virus burden. J Infect Dis 1999;180:2039-43. 
 11.  Isaac A, Taylor s, Cane P, Smit E, Gibbons SE, White DJ, Drake SM, Khoo S, Back DJ. 
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and 
pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother 2004;54:498-502. 
 12.  Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies 
between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in 
human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47:238-
43. 
 13.  Kappelhoff BS, Van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and 
efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005;10:145-
55. 
 14.  Kappelhoff BS, Crommentuyn KM, De Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical 
guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 
2004;43:845-53. 
 15.  Anonymous. Optimising TDM in HIV clinical care. A practical guide to performing therapeutic 
drug monitoring (TDM) for antiretroviral agents. Available: http://www HIVpharmacology com 
Last visited on July, 5, 2005 2003. 
 16.  Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions 
amongst antiretroviral agents used to treat patients with HIV infection. Drug Interactions 
1999;36:289-304. 
 17.  Burger DM, Hoetelmans RMW, Koopmans PP, Meenhorst PL, Mulder JW, Hekster YA, Beijnen 
J. Clinically relevant drug interactions with antiretroviral agents. Antiviral Therapy 1997;2:149-
65. 
 18.  Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. 
Ther Drug Monit 2001;23:591-605. 
 19.  Kosel BW, Aweeka F. Drug interactions of antiretroviral agents. AIDS Clin Rev 2000;193-227. 
 20.  Sheehan NL, Kelly DV, Tseng AL, van Heeswijk RP, Beique LC, Hughes CA. Evaluation of HIV 
drug interaction web sites. Ann Pharmacother 2003;37:1577-86. 
 21.  Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF. HIV seroprevalence by anonymous 
testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet 
2000;356:1488-89. 
 22.  Msamanga GI, Fawzi WW. The double burden of HIV infection and tuberculosis in sub-Saharan 
Africa. N Engl J Med 1997;337:849-51. 
 23.  Schluger NW. Issues in the treatment of active tuberculosis in human immunodeficiency virus-
infected patients. Clinical Infectious Diseases 1999;1999:130-135. 
 24.  Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and 
pharmacokinetics. Clin Pharmacokinet 2004;43:595-612. 
General discussion 
 
140 
 25.  Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with 
acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-35. 
 26.  Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic 
safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune 
Defic Syndr 2003;34 Suppl 1:S21-S33. 
 27.  Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar 
C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, 
Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with 
zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 
012 randomised trial. Lancet 1999;354:795-802. 
 28.  Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev 
2002;4:59-63. 
 29.  Viramune® Summary of Product Characteristics. Boehringer Ingelheim International GmbH, 
Ingelheim am Rhein, Germany . 1999. 
 
 
 
  
  
   143 
Summary 
 
This thesis intended to make a contribution to therapeutic drug monitoring (TDM) of HIV 
treatment and bridging the laboratory and clinic. 
In the introduction (Part I) of this thesis the main groups of antiretroviral drugs are described 
and the role of TDM in the management of HIV is outlined. Furthermore, the various chapters 
of this thesis are introduced. 
 
In Part II topics related to chemical analysis of antiretroviral drugs are presented. A 
requirement for TDM is the plasma level of the antiretroviral drugs. In chapter 1 a high-
performance liquid chromatographic method for the simultaneous determination of protease 
inhibitors and nevirapine in human plasma is described. This method is a simple accurate 
and precise assay and this analysis can be applied for pharmacokinetic studies and for TDM 
of HIV-infected patients. 
In chapter 2 the long-term stability of protease inhibitors in human plasma at different 
temperatures was studied. After 18 months of storage in the freezer concentrations found 
varied between 95% and 108% of the initial concentration, so all protease inhibitors studied 
were stable at -20°C and at -80°C for at least 18 months. In order to produce accurate results 
when analyzing plasma samples for pharmacokinetic studies, it is important to know that 
these samples are stable in the freezer. 
In Chapter 3 the false positive results for efavirenz and rifampin in a urine drug-screening 
assay are described. Clinicians, technicians, and researchers should be aware of the 
possibility of false positive results. 
 
Part III focused on the quality of TDM services. Because plasma concentrations of 
antiretroviral drugs are an essential starting point for TDM, these concentrations should be 
analyzed accurately. In chapter 4 the results of the third round of the international 
interlaboratory quality control program are described, in which participating laboratories were 
asked to measure protease inhibitors and nonnucleoside reverse transcriptase inhibitors in 
human plasma. This program revealed a large variability of laboratories to measure 
antiretroviral drugs accurately. Only 3 out 30 laboratories performed all their measurements 
within the accuracy limits and of all the measurements about 20% were without the 
acceptable ranges. The low concentrations were more difficult to measure accurately than 
the medium and high concentrations. Sources of error were inquired and the most errors 
were technical problems. The results of this study may have important implications for TDM 
and pharmacokinetic studies. 
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In chapter 5 the results of a patient case that was also part of the third round of the 
international interlaboratory quality control program are presented. The case was composed 
of different topics related to TDM and the participants were asked to give their 
recommendations. Of the 30 participants in the program, only 16 returned their 
recommendations. The drug level was judged correctly by about 90% of the participants. On 
the other hand, only half of the recommendations given were satisfactory. Therefore, the 
quality program is not only a tool to alert laboratories to undetected analytical problems, but 
is also useful to realize that recommendations regarding dose adjustment, changing of a 
regimen, or concomitant medication, cannot be given without proper knowledge.  
 
In Part IV of this thesis pharmacokinetic studies are presented. In chapter 6 the penetration 
of lopinavir in seminal plasma was studied. Lopinavir had a poor penetration in the seminal 
plasma, as the median ratio (N=14) of the concentrations of lopinavir in seminal plasma and 
in blood plasma was only 0.034.  
Chapter 7 and 8 were devoted to interaction studies with tenofovir disoproxil fumarate (DF). 
The study in chapter 7 has assessed the effect of rifampin on the pharmacokinetics and 
tolerability of tenofovir DF in healthy volunteers. All subjects were given tenofovir DF at 300 
mg once daily from days 1 to 10. From days 11 to 20 the subjects received tenofovir DF at 
300 mg combined with rifampin at 600 mg once daily. The multiple-dose pharmacokinetics of 
tenofovir (day 10 and 20) and rifampin (day 20) were assessed. The drug-related adverse 
events (AEs) experienced during this study were mostly mild. Point estimates for the mean 
ratios of tenofovir with rifampin versus tenofovir alone for the area under the concentration-
time curve from time zero to 24 h (AUC0-24), the maximum concentration of drug in plasma 
(Cmax), and the minimum concentration of drug in plasma (Cmin) were 0.88, 0.84, and 0.85 
respectively. The 90% classical confidence intervals for AUC0-24, Cmax, Cmax, and Cmin were 
0.84 to 0.92, 0.78 to 0.90, and 0.80 to 0.91, respectively, thus suggesting pharmacokinetic 
equivalence. Similarly, coadministration of rifampin and tenofovir DF did not result in 
changes in the values of the tenofovir pharmacokinetic parameters. For rifampin, the values 
of the pharmacokinetic parameters found in this study were comparable to those found in the 
literature, indicating that tenofovir DF has no effect on the pharmacokinetics of rifampin. In 
conclusion, adaptation of either the rifampin or tenofovir DF dose for the simultaneous 
treatment of tuberculosis and human immunodeficiency virus (HIV) infection in HIV-infected 
patients is probably not required. 
In chapter 8 coadministration of tenofovir DF with efavirenz or nevirapine in HIV-infected 
patients was studied. Data were retrospectively collected from routine TDM plasma samples. 
Nevirapine, efavirenz, and tenofovir plasma levels, and tenofovir concentration ratios were 
analyzed. Six different groups were studied; 200 mg NVP twice daily, 400 mg NVP once 
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daily, 600 mg EFV once daily, all without tenofovir DF (group 1, 2, and 3, respectively), and 
the same groups combined with tenofovir 300 mg once daily (group 4, 5, and 6, 
respectively). 
No difference in plasma levels for tenofovir, nevirapine, and efavirenz were found for either 
one of the combinations studied. Addition of tenofovir DF to efavirenz or nevirapine in HIV-
infected patients does not influence the plasma levels of nevirapine or efavirenz. 
Furthermore, nevirapine and efavirenz have no effect on tenofovir plasma levels and 
tenofovir concentration ratios. 
Efavirenz or nevirapine can be coadministered with tenofovir DF in HIV-infected patients 
without dose modifications 
Single-dose nevirapine is used to reduce mother-to-child transmission (MTCT) in resource 
limited countries. Enthusiasm for the use of nevirapine for MTCT has been tempered by the 
observation that exposure of pregnant women to single-dose nevirapine is frequently 
associated with the development of resistance. The data in chapter 9 demonstrated that the 
time to the first undetectable nevirapine plasma concentration varied from 10 days to more 
than 21 days. This information is valuable for designing intervention studies to prevent the 
development of nevirapine resistance. 
 
In the general discussion (Part V) the main findings are discussed and final thoughts on 
future research are given. 
 
At TDM-services a close collaboration between laboratory and clinic is essential.  
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Samenvatting 
 
Met dit proefschrift is getracht om een bijdrage te leveren aan de therapeutic drug monitoring 
(TDM) van de HIV-behandeling en om een brug te slaan tussen laboratorium en kliniek. 
In de inleiding (Deel I) van dit proefschrift worden de belangrijkste groepen van de 
antiretrovirale middelen beschreven en de rol van TDM bij de behandeling van HIV. 
Daarnaast worden de verschillende hoofdstukken in dit proefschrift kort aangestipt. 
 
In Deel II worden onderwerpen die gerelateerd zijn aan de chemische analyse van 
antiretrovirale middelen gepresenteerd. Een vereiste voor TDM is de plasmaspiegel van de 
antiretrovirale middelen. In hoofdstuk 1 is een hoge-druk vloeistof chromatografische 
methode beschreven voor de gelijktijdige bepaling van proteaseremmers en nevirapine in 
humaan plasma. Deze methode is eenvoudig, accuraat en precies en deze analyse kan 
gebruikt worden voor farmacokinetisch onderzoek en TDM in HIV-geïnfecteerde patiënten. 
In hoofdstuk 2 is de stabiliteit van proteaseremmers in humaan plasma bij verschillende 
temperaturen op lange termijn bestudeerd. Na 18 maanden opslag in de diepvries 
varieerden de gevonden concentraties tussen de 95% en 108% van de initiële concentraties, 
dus alle proteaseremmers die bestudeerd werden, zijn stabiel bij -20°C en bij -80°C 
gedurende tenminste 18 maanden. Het is belangrijk te weten dat dit soort monsters stabiel 
zijn in de vriezer zodat ook na bewaren accurate uitslagen geproduceerd kunnen worden 
voor farmacokinetisch onderzoek. 
In hoofdstuk 3 worden de vals-positieve resultaten van efavirenz en rifampicine beschreven 
in een urine drug-screening assay. Artsen, analisten en onderzoekers moeten zich bewust 
zijn van de mogelijkheid van vals positieve resultaten. 
 
In Deel III wordt aandacht besteed aan de kwaliteit van TDM services. Aangezien 
plasmaconcentraties van antiretrovirale middelen een essentieel uitgangspunt zijn voor TDM, 
moeten deze concentraties accuraat geanalyseerd worden. In hoofdstuk 4 worden de 
resultaten van de derde ronde van het internationaal interlaboratorium kwaliteitscontrole 
programma beschreven, waarin deelnemende laboratoria gevraagd werden om 
proteaseremmers en nonnucleoside reverse transcriptase remmers te meten in humaan 
plasma. Dit programma liet zien dat er grote verschillen tussen de laboratoria bestaan in hun 
vermogen om antiretrovirale middelen accuraat te kunnen meten. Slechts 3 van de 30 
laboratoria rapporteerden al hun metingen binnen de vooraf gestelde grenzen (80% tot120% 
van de werkelijke waarde) en van alle metingen viel ongeveer 20% buiten de vooraf gestelde 
grenzen. De lage concentraties waren moeilijker accuraat te meten dan de medium en hoge 
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concentraties. Er werd navraag gedaan naar mogelijke foutenbronnen en het bleek dat de 
meeste fouten van technische aard waren. De resultaten van deze studie kunnen belangrijke 
gevolgen hebben voor TDM en farmacokinetisch onderzoek. 
In hoofdstuk 5 worden de resultaten van een patiëntencasus, die ook deel uitmaakte van de 
derde ronde van het internationaal interlaboratorium kwaliteitscontrole programma, 
gepresenteerd. De casus bestond uit verschillende onderwerpen die gerelateerd zijn aan 
TDM en aan de deelnemers werd gevraagd om hun aanbevelingen te geven. Van de 30 
deelnemers aan het programma, stuurden slechts 16 hun aanbevelingen op. De 
bloedspiegels van de geneesmiddelen werden correct beoordeeld door ongeveer 90% van 
de deelnemers. Daartegenover stond dat maar de helft van de aanbevelingen correct was. 
Daarom is het kwaliteitscontrole programma niet alleen een hulpmiddel om laboratoria 
opmerkzaam te maken op niet eerder ontdekte analytische problemen, maar ook nuttig om 
te realiseren dat aanbevelingen betreffende dosisaanpassing, veranderen van regime of 
comedicatie niet gegeven kunnen worden zonder de juiste kennis. 
 
In Deel IV van dit proefschrift worden farmacokinetische onderzoeken gepresenteerd. In 
hoofdstuk 6 werd de penetratie van lopinavir in seminaal plasma bestudeerd. De mediane 
ratio (N=14) van de concentratie van lopinavir in seminaal plasma versus de concentratie 
van lopinavir in bloed plasma was slechts 0.034, wat betekent dat lopinavir slecht penetreert 
in seminaal plasma. 
In hoofdstuk 7 and 8 zijn onderzoeken naar mogelijke interacties met tenofovir disoproxil 
fumaraat (DF) het onderwerp. Het onderzoek in hoofdstuk 7 heeft het effect van rifampicine 
op de farmacokinetiek en de verdraagzaamheid van tenofovir DF in gezonde vrijwilligers 
geëvalueerd. Alle personen kregen éénmaal daags 300 mg tenofovir DF mg gedurende dag 
1 tot en met dag 10. Gedurende dag 11 tot en met 20 kregen alle personen éénmaal daags 
300 mg tenofovir DF gecombineerd met 600 mg rifampicine. De farmacokinetiek van 
tenofovir (dag 10 en 20) en rifampicine (dag 20) werd vastgesteld. De geneesmiddel 
gerelateerde bijwerkingen die gedurende het onderzoek werden gemeld waren voornamelijk 
mild van aard. De geometrisch gemiddelde ratios voor tenofovir met rifampicine versus 
tenofovir alleen voor de oppervlakte onder de tijd-concentratie curve van 0 tot 24 uur (AUC0-
24), de maximale concentratie van drug in plasma (Cmax), en de minimale concentratie van 
drug in plasma (Cmin) waren respectievelijk 0.88, 0.84 en 0.85. De 90% klassieke 
betrouwbaarheidsintervallen voor AUC0-24, Cmax en Cmin waren 0.84 tot 0.92, 0.78 tot 0.90 en 
0.80 tot 0.91 respectievelijk, dus er kan farmacokinetische equivalentie gesuggereerd 
worden. Derhalve kan gesteld worden dat gelijktijdig gebruik van rifampicine en tenofovir DF 
niet in veranderingen van farmacokinetische parameters van tenofovir resulteerde. Wat 
betreft rifampicine waren de farmacokinetische parameters die in dit onderzoek werden 
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gevonden vergelijkbaar met die uit de literatuur. Dit duidt erop dat tenofovir DF geen effect 
heeft op de farmacokinetiek van rifampicine. Daarom kan geconcludeerd worden dat 
dosisaanpassing van zowel tenofovir DF als rifampicine voor de gelijktijdige behandeling van 
tuberculose en HIV waarschijnlijk niet nodig is. 
In hoofdstuk 8 wordt de combinatie van tenofovir DF met efavirenz of nevirapine bij HIV-
geïnfecteerde patiënten bestudeerd. Data werden retrospectief verzameld vanuit routine 
TDM plasmamonsters. Nevirapine, efavirenz en tenofovir plasmaspiegels en tenofovir 
concentratie-ratios werden geanalyseerd. Er werden zes verschillende groepen bestudeerd: 
200 mg NVP tweemaal daags, 400 mg NVP éénmaal daags, 600 mg EFV éénmaal daags, 
alledrie zonder tenofovir DF (groep 1, 2 en 3) en dezelfde groepen gecombineerd met 
éénmaal daags 300 mg tenofovir DF (groep 4, 5 en 6). 
Er werd geen verschil in plasmaspiegels gevonden voor tenofovir, nevirapine of efavirenz 
voor geen enkele combinatie die bestudeerd werd. Toevoeging van tenofovir DF aan een 
efavirenz of nevirapine bevattend regime bij HIV-geïnfecteerde patiënten, heeft geen invloed 
op de plasmaspiegels van nevirapine of efavirenz. Daarnaast hebben efavirenz of nevirapine 
geen invloed op de plasmaspiegels of concentratie-ratios van tenofovir. 
Efavirenz of nevirapine kunnen gecombineerd worden met tenofovir DF in HIV-geïnfecteerde 
patiënten, zonder dat dosis aanpassing noodzakelijk is. 
Een éénmalige dosering van nevirapine wordt gebruikt om moeder-op-kind transmissie 
(MTCT) in derdewereld landen te voorkomen. Het enthousiasme voor nevirapine gebruik 
wordt verminderd doordat er aangetoond is dat blootstelling van zwangere vrouwen aan een 
éénmalige dosering van nevirapine regelmatig wordt geassocieerd met de ontwikkeling van 
resistentie. De data in hoofdstuk 9 laten zien dat de tijd tot de eerste ondetecteerbare 
nevirapine spiegel na éénmalige dosering varieerde van 10 dagen tot meer dan 21 dagen. 
Deze informatie is nuttig bij het ontwerpen van interventie-onderzoek om ontwikkeling van 
nevirapine resistentie te voorkomen. 
 
In de algemene discussie (Deelt V) worden de belangrijkste bevindingen bediscussieerd en 
enkelen gedachten over toekomstig onderzoek worden gegeven. 
 
Bij TDM-services is een nauwe samenwerking tussen laboratorium en kliniek van groot 
belang. 
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